Document:

PURCHASE AGREEMENT DATED SEPTEMBER 18, 2003

  
 EXHIBIT 10.26

  
 EXECUTION COPY 
  
 PURCHASE AGREEMENT 
  
 PURCHASE AGREEMENT dated as of September 18, 2003, among 454
Corporation, a Delaware corporation (the “Company”), CuraGen Corporation (“CuraGen”) and the several purchasers named in the attached Schedule 1 (individually a “Purchaser” and collectively
the “Purchasers”). 
  
 WHEREAS, (A) the
Company wishes to issue and sell to CuraGen 6,404,854 shares of the Company’s authorized but unissued Series C Preferred Stock, $0.01 par value per share (the “Series C Preferred Stock”), and (B) the Company wishes to issue and sell
to the Purchasers up to an aggregate of 1,595,146 shares of the Company’s authorized but unissued Series D Preferred Stock, $0.01 par value per share (the “Series D Preferred Stock”); and 
  
 WHEREAS, CuraGen wishes to purchase the Series C Preferred Stock on
the terms and subject to the conditions set forth in this Agreement; and 
  
 WHEREAS, the Purchasers, severally, wish to purchase the Series D Preferred Stock on the terms and subject to the conditions set forth in this Agreement; 
  
 NOW, THEREFORE, in consideration of the premises and the mutual
covenants contained in this Agreement, the parties agree as follows: 
  
 §1. THE SERIES C PREFERRED STOCK AND THE SERIES D PREFERRED STOCK 
  
 §1.01. Issuance, Sale and Delivery of the Series C Preferred Stock and the Series D Preferred Stock. Subject to the terms and conditions hereinafter set forth, (A) the Company hereby agrees to issue
and sell to CuraGen and CuraGen hereby agrees to purchase from the Company, 6,404,854 shares of Series C Preferred Stock at the purchase price of $2.50 per share; and (B) the Company hereby agrees to issue and sell to each Purchaser listed on
Schedule 1, and each such Purchaser hereby agrees to purchase from the Company, the number of shares of Series D Preferred Stock set forth opposite the name of such Purchaser under the heading “Shares of 454 Corporation Series D
Preferred Stock to be Purchased” on Schedule 1, at the purchase price of $2.50 per share. 
  
 §1.02. Closing. The closing shall take place, with executed documents transmitted via telecopy on September 18, 2003, or at such other
date and time as may be agreed upon among the Purchasers, the Company and CuraGen (such closing being called the “Closing” and such date and time being called the “Closing Date”). At the Closing, the Company shall
(i) issue and deliver to CuraGen a stock certificate, registered in the name of CuraGen, representing 6,404,854 shares of Series C Preferred Stock and (ii) issue and deliver to each Purchaser a stock certificate or certificates, registered in the
name of such Purchaser, representing the number of shares of Series D Preferred Stock set forth opposite the name of such Purchaser under the headings “Shares of 454 Corporation Series D Preferred Stock to be Purchased” on Schedule
1. 
  

 §1.03. Payment of Purchase Price. (A) As payment in full for the Series C Preferred
Stock being purchased by it at the Closing, and against delivery of the stock certificate therefor as aforesaid, on the Closing Date for such Closing CuraGen shall deliver to the Company an amount equal to $2.50 for each share of Series C Preferred
Stock being purchased by CuraGen at such Closing. 
  
 (B) As
payment in full for the Series D Preferred Stock being purchased by it at the Closing, and against delivery of the stock certificates therefor as aforesaid, on the Closing Date for such Closing each Purchaser listed on Schedule 1 shall
deliver to the Company an amount equal to $2.50 for each share of Series D Preferred Stock being purchased by such Purchaser at such Closing. 
  
 (C) The payments in Sections 1.03(A) and (B) to the Company shall be referred to collectively as the “Purchase Price.” Payment of the
Purchase Price shall be made by wire transfer in immediately available funds to the account of the Company. 
  
 §2. REPRESENTATIONS AND WARRANTIES OF THE COMPANY 
  
 The Company represents and warrants to the Purchasers that, except as set forth in the Disclosure Schedules attached hereto: 
  
 §2.01. Organization, Qualification and Corporate Power.
The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware. The Company is duly licensed or qualified in each jurisdiction in which the nature of the business transacted by it
requires such licensing or qualification, unless the failure to so qualify does not have a material adverse effect on the business operations or financial condition of the Company. The Company has the corporate power and authority to own and hold
its properties and to carry on its business as now conducted and as proposed to be conducted, to execute, deliver and perform this Agreement, the Amended and Restated Registration Rights Agreement to be dated as of the Closing Date by and among the
Company and the other parties thereto (the “Registration Rights Agreement”), the Waiver and Amendment No. 1 to the Purchase Agreement to be dated as of the Closing Date by and among the Company and the other parties thereto (the
“Waiver Agreement”) and, upon the due filing of the Charter (defined below), to issue, sell and deliver the Series C Preferred Stock and the Series D Preferred Stock and to issue and deliver the shares of Common Stock, $0.01 par
value per share, of the Company (“Common Stock”) issuable upon conversion of the Series C Preferred Stock and Series D Preferred Stock (the “Conversion Shares”). 
  
 §2.02. Authorization of Agreements, etc. 
  
 (a) The execution and delivery by the Company of this
Agreement, the Registration Rights Agreement and the Waiver Agreement, the performance by the Company of its obligations hereunder and thereunder, the issuance, sale and delivery of the Series C Preferred Stock and Series D Preferred Stock and the
issuance and delivery of the Conversion Shares have been duly authorized by all requisite corporate action and will not violate any provision of law, any order of any court or other agency of government, the Certificate of Incorporation of the
Company, as amended by the 

  

 2 

 
Restated Certificate of Incorporation in the form attached hereto as Exhibit A (as so amended, the “Charter”), or the By-laws
of the Company, or any provision of any indenture, agreement or other instrument to which the Company, any of its subsidiaries or any of their respective properties or assets is bound, or conflict with, result in a breach of or constitute (with due
notice or lapse of time or both) a default under any such indenture, agreement or other instrument, or result in the creation or imposition of any lien, charge, restriction, claim or encumbrance of any nature whatsoever upon any of the properties or
assets of the Company or any of its subsidiaries. 
  
 (b) Upon the filing of the Charter, the Series C Preferred Stock and Series D Preferred Stock will have been duly authorized and, when issued in accordance with this Agreement, will be validly issued, fully paid and nonassessable shares of
Series C Preferred Stock and Series D Preferred Stock with no personal liability attaching to the ownership thereof and will be free and clear of all liens, charges, restrictions, claims and encumbrances. Upon the filing of the Charter, the
Conversion Shares will have been duly reserved for issuance upon conversion of the Series C Preferred Stock and Series D Preferred Stock and, when so issued, will be duly authorized, validly issued, fully paid and nonassessable shares of Common
Stock with no personal liability attaching to the ownership thereof and will be free and clear of all liens, charges, restrictions, claims and encumbrances. Neither the issuance, sale nor delivery of the Series C Preferred Stock and the Series D
Preferred Stock nor the issuance or delivery of the Conversion Shares is subject to any preemptive right of stockholders of the Company or to any right of first refusal or other right in favor of any person. 
  
 (c) Validity. This Agreement, the Registration
Rights Agreement and the Waiver Agreement have been duly executed and delivered by the Company and each constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with its terms. 
  
 (d) Authorized Capital Stock. Upon the filing
of the Charter the authorized capital stock of the Company shall consist of (i) 38,000,000 shares of Preferred Stock, $0.01 par value (the “Preferred Stock”), of which (a) 12,000,000 shares have been designated Series A Preferred
Stock, $0.01 par value per share (the “Series A Preferred Stock”), and are issued and outstanding, (b) 8,000,000 shares have been designated Series B Preferred Stock, $0.01 par value per share (the “Series B Preferred Stock”),
and are issued and outstanding, (c) 6,404,854 shares have been designated Series C Preferred Stock and will be issued and outstanding following the Closing, (d) 1,595,146 shares have been designated Series D Preferred Stock and will be issued and
outstanding following the Closing and (e) 10,000,000 shares remain undesignated and (ii) 48,000,000 shares of Common Stock. 47,933 shares of Common Stock are issued or outstanding. Schedule 2.02 attached hereto sets forth the summary
capitalization table of the Company. The designations, powers, preferences, rights, qualifications, limitations and restrictions in respect of each class and series of authorized capital stock of the Company are as set forth in the Charter, a copy
of which is attached as Exhibit A, and all such designations, powers, preferences, rights, qualifications, limitations and restrictions, upon the filing of the Charter, will be valid, binding and enforceable and in accordance with all
applicable laws. Except as set forth above or in the attached Schedule 2.02, (i) no person 

  

 3 

 
owns of record or is known to the Company to own beneficially any share of Common Stock or Preferred Stock, (ii) no subscription, warrant, option,
convertible security, or other right (contingent or other) to purchase or otherwise acquire from the Company (or from any other person or entity) any equity securities of the Company is authorized or outstanding and (iii) there is no commitment by
the Company to issue shares, subscriptions, warrants, options, convertible securities, or other such rights or to distribute to holders of any of its equity securities any evidence of indebtedness or asset. Except as provided for in the Charter or
as set forth in the attached Schedule 2.02, the Company has no obligation (contingent or other) to purchase, redeem or otherwise acquire any of its equity securities or any interest therein or to pay any dividend or make any other
distribution in respect thereof. There are no voting trusts or agreements, stockholders’ agreements, pledge agreements, buy-sell agreements, rights of first refusal, preemptive rights or proxies relating to any securities of the Company or any
of its subsidiaries (whether or not the Company or any of its subsidiaries is a party thereto). All of the outstanding securities of the Company were issued in compliance with all applicable federal and state securities laws. 
  
 §2.03. Litigation, Compliance with Law. There is no (i)
action, suit, claim, proceeding or investigation pending or, to the best of the Company’s knowledge, threatened against or affecting the Company, at law or in equity, or before or by any Federal, state, municipal or other governmental
department, commission, board, bureau, agency or instrumentality, domestic or foreign, (ii) arbitration proceeding relating to the Company pending under collective bargaining agreements or otherwise, or (iii) governmental inquiry pending or, to the
best of the Company’s knowledge, threatened against or affecting the Company (including without limitation any inquiry as to the qualification of the Company to hold or receive any license or permit), and, to the best of the Company’s
knowledge, there is no basis for any of the foregoing. The Company is not in default with respect to any order, writ, injunction or decree known to or served upon the Company of any court or of any Federal, state, municipal or other governmental
department, commission, board, bureau, agency or instrumentality, domestic or foreign. There is no action or suit by the Company pending or threatened against others. To the best of the Company’s knowledge, the Company has complied in all
material respects with all laws, rules, regulations and orders applicable to its business, operations, properties, assets, products and services, and the Company has all necessary permits, licenses and other authorizations required to conduct its
business as conducted and as proposed to be conducted. There is no existing law, rule, regulation or order, and the Company is not aware of any proposed law, rule, regulation or order, whether Federal or state, which would prohibit or restrict the
Company from, or otherwise materially adversely affect the Company in, conducting its business in any jurisdiction in which it is now conducting business or in which it proposes to conduct business. 
  
 §2.04. Title to Properties. The Company has good and
marketable title to all of its properties and assets, and all such properties and assets are free and clear of mortgages, pledges, security interests, liens, charges, claims, restrictions and other encumbrances, except for liens for or current taxes
not yet due and payable and minor imperfections of title, if any, not material in nature or amount and not materially detracting from the value or impairing the use of the property subject thereto or impairing the operations or proposed operations
of the Company. 
  

 4 

 §2.05. Taxes. The Company has filed all tax returns, Federal, state, county and local,
required to be filed by it, and the Company has paid all taxes shown to be due by such returns as well as all other taxes, assessments and governmental charges which have become due or payable, including without limitation all taxes which the
Company is obligated to withhold from amounts owing to employees, creditors and third parties. There is no tax lien, whether imposed by any Federal, state, county or local taxing authority, outstanding against the assets, properties or business of
the Company. 
  
 §2.06. Other Agreements. The
Company is in full compliance with all of the terms and provisions of its Charter, By-laws and any agreement, instrument, judgment, decree, order, statute, rule or government regulation applicable to the Company or to which the Company is a party,
where any violation, noncompliance or default would materially and adversely affect or could materially and adversely affect the business, prospects, financial condition, operations, property or affairs of the Company or any of its subsidiaries.

  
 §2.07. Governmental Approvals. Subject to
the accuracy of the representations and warranties of CuraGen and the Purchasers set forth in Section 3, no registration or filing with, or consent or approval of or other action by, any Federal, state or other governmental agency or instrumentality
is or will be necessary for the valid execution, delivery and performance by the Company of this Agreement, the Registration Rights Agreement or the Waiver Agreement, the issuance, sale and delivery of the Series C Preferred Stock and Series D
Preferred Stock or, upon conversion thereof, the issuance and delivery of the Conversion Shares, other than filings pursuant to federal and state securities laws in connection with the sale of the Series C Preferred Stock and Series D Preferred
Stock. 
  
 §2.08. Disclosure. The
Company’s representations and warranties in this Agreement and in the Schedules and Exhibits to this Agreement, do not contain any untrue statement of a material fact or omit a material fact necessary to make the statements contained herein or
therein not misleading. None of the statements, documents, certificates or other items prepared or supplied by the Company with respect to the transactions contemplated hereby contains an untrue statement of a material fact or omits a material fact
necessary to make the statements contained therein not misleading. There is no fact which the Company has not disclosed to CuraGen and the Purchasers and their counsel in writing and of which the Company is aware which materially and adversely
affects or could materially and adversely affect the business, prospects, financial condition, operations, property or affairs of the Company or any of its subsidiaries. 
  
 §2.09. Offering of the Series C Preferred Stock and Series D Preferred Stock. Neither the Company nor any
person authorized or employed by the Company as agent, broker, dealer or otherwise in connection with the offering or sale of the Series C Preferred Stock and Series D Preferred Stock or any security of the Company similar to the Series C Preferred
Stock and Series D Preferred Stock has offered the Series C Preferred Stock or the Series D Preferred Stock or any such similar security for sale to, or solicited any offer to buy the Series C Preferred Stock or the Series D Preferred Stock or any
such similar security from, or otherwise approached or negotiated with respect thereto with, any person or persons, and neither the Company nor any person acting on its behalf has taken or will take any other action (including, without limitation,
any offer, issuance or sale of any security of the Company under circumstances which might 

  

 5 

 
require the integration of such security with Series C Preferred Stock or Series D Preferred Stock under the Securities Act or the rules and regulations of
the Commission thereunder), in either case so as to subject the offering, issuance or sale of the Series C Preferred Stock or the Series D Preferred Stock to the registration provisions of the Securities Act. 
  
 §2.10. Brokers. The Company has no contract, arrangement
or understanding with any broker, finder or similar agent with respect to the transactions contemplated by this Agreement. 
  
 §2.11. Ownership and Nondisclosure Agreement. Each employee, consultant and contractor of the Company identified on Schedule
2.11 has entered into and executed a Ownership and Nondisclosure Agreement in the form attached to this Agreement as Exhibit B or an employment or consulting agreement containing substantially similar terms. 
  
 §2.12. Status of Proprietary Assets. 
  
 (a) Ownership. To the best of its knowledge and
except as set forth on Schedule 2.12(a), the Company has full title and ownership of, or has license to, all patents, patent applications, trademarks, service marks, trade names, copyrights, moral rights, mask works, trade secrets,
confidential and proprietary information, compositions of matter, formulas, designs, proprietary rights, know-how and processes (all of the foregoing collectively referred to as the “Proprietary Assets”) necessary to enable it to
carry on its business as now conducted and as presently proposed to be conducted, without any conflict with or infringement of the rights of others. A complete list of all the Company’s material Proprietary Assets is set forth on Schedule
2.12(b) to this Agreement. Except as set forth on Schedule 2.12(a), to the best of the Company’s knowledge, no third party has any ownership right, title, interest, claim in or lien on any of the Company’s Proprietary
Assets and the Company has taken commercially reasonable steps necessary to preserve its legal rights in, and the secrecy of, all its Proprietary Assets, except those for which disclosure is required for legitimate business or legal reasons.

  
 (b) Licenses; Other Agreements. Except
as set forth on Schedule 2.12(a), the Company has not granted, and, there are not outstanding, any options, licenses or agreements of any kind relating to any Proprietary Asset of the Company, nor, except as set forth on Schedule
2.12(a), is the Company bound by or a party to any option, license or agreement of any kind with respect to any of its Proprietary Assets. Except as set forth on Schedule 2.12(a), the Company is not obligated to pay any
royalties or other payments to third parties with respect to the marketing, sale, distribution, manufacture, license or use of any Proprietary Assets or any other property or rights. 
  
 (c) No Infringement. To the best of the Company’s knowledge, the Company has not violated or
infringed, and is not currently violating or infringing, and the Company has not received any communications alleging that the Company (or any of its employees or consultants) has violated or infringed or, by conducting its business as proposed,
would violate or infringe, any Proprietary Asset of any other person or entity. 
  
 (d) No Breach by Employee. The Company is not aware that any employee or consultant of the Company is obligated under any agreement
(including licenses, covenants or commitments of any nature) or subject to any judgment, decree or order of any 

  

 6 

 
court or administrative agency, or any other restriction that would interfere with the use of his or her best efforts to carry out his or her duties for the
Company or to promote the interests of the Company or that would conflict with the Company’s business as proposed to be conducted. The carrying on of the Company’s business by the employees and contractors of the Company and the conduct of
the Company business as presently proposed, will not, to the best of the Company’s knowledge, conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant or instrument
under which any of such employees or contractors or the Company is now obligated. The Company does not believe it is or will be necessary to utilize any inventions of any employees of the Company (or persons the Company currently intends to hire)
made prior to their employment by the Company which have not otherwise become property of the Company. At no time during the conception of or reduction of any of the Proprietary Assets to practice was any developer, inventor or other contributor to
such patents operating under any grants from any governmental entity or agency or private source, performing research sponsored by any governmental entity or agency or private source or subject to any employment agreement or invention assignment or
nondisclosure agreement or other obligation with any third party that could adversely affect the Company’s rights in such Proprietary Assets. 
  
 §2.13. Financial Statements. 
  
 (a) The Company has delivered to the Purchasers (a) audited balance sheets of the Company as of December 31 in each of the years 2001 and
2002 (such 2002 balance sheet, including the notes thereto, is referred to herein as the “Balance Sheet”), and the related audited statements of income, changes in stockholders’ equity and cash flow and the notes thereto for each of
the fiscal years then ended, together with the report thereon of the Company’s independent certified public accountants, and (b) an unaudited balance sheet of the Company as of June 30, 2003 (the “Interim Balance Sheet”) and the
related unaudited statements of income, changes in stockholders’ equity, and cash flow for the six months then ended, which have been reviewed by the Company’s independent certified public accountants in the context of reviewing
CuraGen’s quarterly report on Form 10-Q. Such financial statements and notes fairly present the financial condition and the results of operations, changes in stockholders’ equity and cash flow of the Company as of the respective dates of
and for the periods referred to in such financial statements, all in accordance with GAAP, subject, in the case of interim financial statements, to normal recurring year-end adjustments (the effect of which will not, individually or in the
aggregate, be materially adverse) and the absence of notes (that, if presented, would not differ materially from those included in the Balance Sheet); the financial statements referred to in this Section 2.13 reflect the consistent application of
such accounting principles throughout the periods involved, except as disclosed in the notes to such financial statements. No financial statements of any person other than the Company are required by GAAP to be included in the financial statements
of the Company. 
  
 (b) Except as disclosed in
Schedule 2.13(b) hereto, the Company has no liabilities or obligations of any nature (whether known or unknown and whether absolute, accrued, contingent or otherwise) except for liabilities or obligations reflected or reserved against the
Balance Sheet or the Interim Balance Sheet and current liabilities incurred in the ordinary course of business since the respective dates thereof. 
  

 7 

 (c) Since the date of the Balance Sheet, there has not been any material adverse change
in the business, operations, properties, prospects, assets or condition of the Company, and no event has occurred or circumstance exists that may result in such a material adverse change. 
  
 §3. REPRESENTATIONS AND WARRANTIES OF CURAGEN AND THE PURCHASERS 
  
 For the purposes of this Section 3, the term “Purchaser” shall
include CuraGen. Each Purchaser severally represents and warrants to the Company that: 
  
 (a) such Purchaser is an “accredited investor” within the meaning of Rule 501 of Regulation D under the Securities; 

 
 (b) such Purchaser has sufficient knowledge and
experience in investing in companies similar to the Company in terms of the Company’s stage of development so as to be able to evaluate the risks and merits of such Purchaser’s investment in the Company and such Purchaser is able
financially to bear the risks thereof; 
  
 (c)
such Purchaser has had an opportunity to discuss the Company’s business, management and financial affairs with the management of the Company; 
  
 (d) the securities being purchased by such Purchaser are being acquired for such Purchaser’s own account for the purpose of
investment and not with a view to or for sale in connection with any distribution thereof; and 
  
 (e) such Purchaser understands that (i) the securities (the Series C Preferred Stock, the Series D Preferred Stock and the Conversion
Shares) have not been registered under the Securities Act by reason of their issuance in a transaction exempt from the registration requirements of the Securities Act pursuant to Section 4(2) thereof or Rule 506 promulgated under the Securities Act,
(ii) the Series C Preferred Stock and Series D Preferred Stock and, upon conversion or exercise thereof, the Conversion Shares, must be held indefinitely unless a subsequent disposition thereof is registered under the Securities Act or is exempt
from such registration, (iii) each of the shares of Series C Preferred Stock, the shares of Series D Preferred Stock and the Conversion Shares will bear a legend to such effect and (iv) the Company will make a notation on its transfer books to such
effect. 
  

 8 

 §4. CONDITIONS TO THE OBLIGATIONS OF THE PURCHASERS 
  
 The obligation of CuraGen and each Purchaser to purchase and pay for Series
C Preferred Stock or Series D Preferred Stock to be purchased by it on a Closing Date is, at CuraGen or such Purchaser’s option, subject to the satisfaction, on or before such Closing Date, of the following conditions: 
  
 §4.01. Opinion of Company’s Counsel. CuraGen and the
Purchasers shall have received from Day, Berry & Howard LLP, counsel for the Company, an opinion dated the Closing Date, substantially in the form of Exhibit C attached to this Agreement. 
  
 §4.02. All Proceedings to be Satisfactory. All corporate
and other proceedings to be taken by the Company in connection with the transactions contemplated hereby and all documents incident thereto shall be satisfactory in form and substance to CuraGen, the Purchasers and their respective counsel, and
CuraGen, the Purchasers and their respective counsel shall have received all such counterpart originals or certified or other copies of such documents as they reasonably may request. 
  
 §4.03. Supporting Documents. CuraGen, the Purchasers and their respective counsel shall have received
copies of the following documents: 
  
 (a) a
certificate of the Secretary of State of the State of Delaware dated as of a recent date as to the existence and good standing of the Company; 
  
 (b) a certificate of the Chief Executive Officer of the Company, on behalf of the Company, dated the Closing Date and certifying: (i) that
attached thereto is a true and complete copy of the Charter and Bylaws of the Company as in effect on the date of such certification; (ii) that attached thereto is a true and complete copy of all resolutions adopted by the Board of Directors of the
Company authorizing the execution, delivery and performance of this Agreement, the Registration Rights Agreement and the Waiver Agreement, the designation, issuance, sale and delivery of the Series C Preferred Stock and the Series D Preferred Stock
and the reservation, issuance and delivery of the Conversion Shares, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated by this Agreement; (iii) each of the
representations and warranties as set forth in Section 2 hereof is true and correct in all material respects except for those representations or warranties that are qualified by materiality or material adverse effect, and each of the representations
and warranties as set forth in Section 2 hereof that is qualified by materiality or material adverse effect is true and correct in all respects; and 
  
 (c) such additional supporting documents and other information with respect to the operations and affairs of the Company as CuraGen, the
Purchasers or their respective counsel reasonably may request. 
  
 §4.04. Registration Rights Agreement. The Company and each of the other parties thereto (other than CuraGen and the Purchaser) shall have executed and delivered the Registration Rights Agreement in the form attached
hereto as Exhibit D. 
  

 9 

 §4.05. Waiver Agreement. The Company and each of the other parties thereto (other than
CuraGen and the Purchaser) shall have executed and delivered the Waiver Agreement in the form attached hereto as Exhibit E. 
  
 Such document required under this Section 4 shall be satisfactory in form and substance to CuraGen, the Purchasers and their respective counsel.

  
 §5. COVENANTS OF THE COMPANY 
  
 For the purposes of this Section 5, the term “Purchaser” shall
include CuraGen. The Company covenants and agrees with each of the Purchasers that so long as such Purchaser owns any of the Series C Preferred Stock, Series D Preferred Stock or Conversion Shares, and until such time as the completion of an
underwritten public offering of the Company’s securities pursuant to which the aggregate price paid by the public for the purchase of securities is at least $30,000,000 (the “Initial Public Offering”) shall have occurred:

  
 §5.01. Financial Statements, Reports, etc.
The Company shall furnish to each Purchaser: 
  
 (a) within ninety (90) days after the end of each fiscal year of the Company, a consolidated balance sheet of the Company and its subsidiaries as of the end of such fiscal year and the related consolidated statements of income,
stockholders’ equity and cash flows for the fiscal year then ended, prepared in accordance with generally accepted accounting principles and audited by a firm of independent public accountants of recognized national standing selected by the
Board of Directors of the Company and reasonably acceptable to the Purchasers; and 
  
 (b) within forty-five (45) days after the end of each fiscal quarter in each fiscal year (other than the last fiscal quarter in each
fiscal year), a consolidated balance sheet of the Company and its subsidiaries and the related consolidated statements of income, stockholders’ equity and cash flows, unaudited but prepared in accordance with generally accepted accounting
principles and certified by the Chief Financial Officer of the Company, such consolidated balance sheet to be as of the end of such fiscal quarter and such consolidated statements of income, stockholders’ equity and cash flows to be for such
fiscal quarter and for the period from the beginning of the fiscal year to the end of such fiscal quarter, in each case with comparative statements for the corresponding period in the prior fiscal year. 
  
 §5.02. Corporate Existence. The Company shall maintain and
cause each of its subsidiaries to maintain their respective corporate existence, rights and franchises in full force and effect. 
  
 §5.03. Properties, Business, Insurance. The Company shall maintain and cause each of its subsidiaries to maintain as to their
respective properties and business, with financially sound and reputable insurers, insurance against such casualties and contingencies and of such types and in such amounts as is customary for companies similarly situated, which insurance shall be
deemed by the Company to be sufficient. 
  

 10 

 §5.04. Inspection, Consultation and Advice. The Company shall permit and cause each of
its subsidiaries to permit each Purchaser and such persons as it may designate, at such Purchaser’s expense, to visit and inspect any of the properties of the Company and its subsidiaries, examine their books and take copies and extracts
therefrom, discuss the affairs, finances and accounts of the Company and its subsidiaries with their officers, employees and public accountants (and the Company hereby authorizes said accountants to discuss with such Purchaser and such designees
such affairs, finances and accounts), and consult with and advise the management of the Company and its subsidiaries as to their affairs, finances and accounts, all at reasonable times and upon reasonable notice. 
  
 §5.05. Keeping of Records and Books of Account. The
Company shall keep, and cause each subsidiary to keep, adequate records and books of account, in which complete entries will be made in accordance with generally accepted accounting principles consistently applied, reflecting all financial
transactions of the Company and such subsidiary, and in which, for each fiscal year, all proper reserves for depreciation, depletion, obsolescence, amortization, taxes, bad debts and other purposes in connection with its business shall be made.

  
 §5.06. Payment of Taxes. The Company shall
pay and discharge all taxes, assessments and governmental charges or levies imposed upon it or upon its income, profits or business, or upon any properties belonging to it, prior to the date on which penalties attach thereto, and all lawful claims
which, if unpaid, might become alien or charge upon any properties of the Company, provided that the Company shall not be required to pay any such tax, assessment, charge, levy or claim which is being contested in good faith and by appropriate
proceedings if the Company shall have set aside on its books sufficient reserves, if any, with respect thereto, or where the failure to so pay materially and adversely affects or could materially and adversely affect the business, prospects,
financial condition, operations, property or affairs of the Company or any of its subsidiaries. 
  
 §6. OBSERVER RIGHTS 
  
 §6.01. Termination of Existing Observer Rights. The group consisting of CLSP, L.P., CLSP II, L.P., CLSP-SBS I, L.P. and CLSP-SBS II,
L.P. (collectively, the “Casdin Group”) hereby waive for all time any and all rights it (or any of its successors) had or have under Section 7 of that certain Purchase Agreement dated as of June 6, 2000 among the Company, CuraGen
and the Purchasers (as defined therein) (the “Series B Purchase Agreement”). 
  
 §6.02. Appointment of Observer. The Casdin Group shall have the right to agree upon and designate, in a non-voting observer capacity, one representative of the Casdin Group reasonably
acceptable to the Company (“Designee”) to attend and observe all meetings of the Company’s Board of Directors (the “Board”) (whether in person, telephonic or otherwise) and such Designee shall be entitled to
receive notices of and to attend meetings of the Board, concurrently with the members of the Board, and in the same manner. If the Designee is unable to attend a Board meeting, the Casdin Group shall have the right to select a replacement Designee
reasonably acceptable to the Company to attend in its place. The right to attend the Board meetings and receive the information described herein shall not apply to (i) the presentation of information or discussions at Board meetings involving
matters which, if provided to or attended by the Designee, or its affiliates (including the Casdin Group entities or 

  

 11 

 
their affiliates), would in the reasonable opinion of counsel to the Company, jeopardize the attorney client privilege that would otherwise be afforded to
such information or meeting or (ii) any particular matter in which the Designee or its affiliates (including the Casdin Group entities or their affiliates) have an interest that in the determination of a majority of the Board conflicts with the
business of the Company. The Casdin Group agrees, and shall cause any Designee to agree in writing prior to attending any meeting of the Board (whether in person, telephonic or otherwise), not to (i) use (for any purpose other than monitoring its
investment in the Company) or (ii) reveal to any person or entity (including any entity or employee of such entity in which the Casdin Group entities and their affiliates has an equity interest) outside of the Casdin Group any confidential
information learned as a result of the rights granted by this Section 6.02 concerning the organization, business or finances of the Company or any information concerning a third party which the Company is under a duty to keep confidential.

  
 §6.03 Termination of Observer Rights. The
observer rights granted to the Casdin Group in Section 6.02 shall terminate and be of no further force or effect immediately prior to the earliest to occur of: 
  

	 	(a)	 	the effective date of the registration statement relating to an Initial Public Offering; or 

  

	 	(b)	 	the consummation of the sale of all, or substantially all, of the Company’s assets or capital stock, either through a direct sale, merger, reorganization, consolidation or
other form of business combination or acquisition in which the Company is the target of such acquisition and/or voting control of the equity securities of the Company is transferred to a third party unaffiliated with the Company.

  
 Furthermore, the observer rights granted to the
Casdin Group in Section 6.02 shall terminate and be of no further force or effect upon the earliest to occur of: 
  

	 	(a)	 	such time as the Casdin Group holds less than 50% of the Series B Preferred Stock and Series D Preferred Stock, taken as a whole, it purchased pursuant to the Series B Purchase
Agreement (with respect to such Series B Preferred Stock) and this Agreement (with respect to such Series D Preferred Stock); or 

  

	 	(b)	 	such time as a director, officer or employee of the Casdin Group or their affiliates becomes a member of the Board. 

  

 12 

 §7. TAG-ALONG RIGHTS 
  
 §7.01. Right to Participate in Sale. 
  
 (a) Opportunity to Participate. If CuraGen proposes to enter into an agreement to sell or otherwise dispose of
for value (such sale or other disposition for value being referred to as a “Tag-Along Sale”) more than 3,073,611 shares (as adjusted for any stock dividends, stock splits, recapitalizations, consolidations or the like) of Common
Stock in a single or series of transactions, then CuraGen shall afford the holders of shares of the Series B Preferred Stock and Series D Preferred Stock the opportunity to participate proportionately in such Tag-Along Sale (the person(s) being
afforded the opportunity to participate proportionately in such Tag-Along Sale being referred to as the “Tag-Along Stockholders”) in accordance with this Section 7. For purposes of this Section 7, the term “Common
Stock” shall include shares of Common Stock issuable upon the conversion of securities convertible into Common Stock. 
  
 (b) Number of Shares. The number of shares of Common Stock that each Tag-Along Stockholder will be entitled to include in such Tag-Along
Sale (the “Tag-Along Allotment”) shall be determined by multiplying (i) the number of shares of Common Stock held by such Tag-Along Stockholder immediately prior to the consummation of the Tag-Along Sale by (ii) a fraction, the
numerator of which shall equal the number of shares of Common Stock proposed to be sold or otherwise disposed of by CuraGen pursuant to the Tag-Along Sale and the denominator of which shall equal the total number of shares of Common Stock that are
beneficially owned by (A) CuraGen and (B) any other holder of shares of Common Stock that had the right to “tag-along” in the Tag-Along Sale on the day immediately prior to the consummation of the Tag-Along Sale Date. 
  
 §7.02. Sale Notice. CuraGen shall provide each Tag-Along
Stockholder and the Company with written notice (the “Tag-Along Sale Notice”) not less than 14 days prior to the proposed date of the Tag-Along Sale (the “Tag-Along Sale Date”). Each Tag-Along Sale Notice shall be
accompanied by a copy of any agreement relating to the Tag-Along Sale (if available) and shall set forth: (a) the name and address of each proposed purchaser of shares of Common Stock in the Tag-Along Sale; (b) the number of shares of Common Stock
proposed to be sold; (c) the proposed amount and form of consideration to be paid for such shares of Common Stock and the terms and conditions of payment offered by each proposed purchaser; (d) the aggregate number of shares of Common Stock held of
record by CuraGen as of the close of business on the day immediately preceding the date of the Tag-Along Notice (the “Tag-Along Notice Date”); (e) the Tag-Along Stockholder’s Tag-Along Allotment assuming the Tag-Along
Stockholder elected to sell the maximum number of shares of Common Stock possible; and (f) the Tag-Along Sale Date. 
  
 §7.03. Tag-Along Notice. Any Tag-Along Stockholder wishing to participate in the Tag-Along Sale shall provide written notice (the
“Tag-Along Notice”) to the party proposing the Tag-Along Sale no less than 7 days prior to the Tag-Along Sale Date. The Tag-Along Notice shall set forth the number of shares of Common Stock that such Tag-Along Stockholder elects to
include in the Tag-Along Sale, which shall not exceed such Tag-Along Stockholder’s Tag-Along Allotment. The Tag-Along Notice given by any Tag-Along Stockholder shall constitute such 

  

 13 

 
Tag-Along Stockholder’s binding agreement to sell the shares of Common Stock specified in the Tag-Along Notice on the terms and conditions applicable to
the Tag-Along Sale; provided, however, that in the event that there is any material change in the material terms and conditions of such Tag-Along Sale applicable to the Tag-Along Stockholder (including, but not limited to, any decrease in the
purchase price that occurs other than pursuant to an adjustment mechanism set forth in the agreement relating to the Tag-Along Sale) after such Tag-Along Stockholder gives its Tag-Along Notice, then, notwithstanding anything herein to the contrary,
the Tag-Along Stockholder shall have the right to withdraw from participation in the Tag-Along Sale with respect to all of its shares of Common Stock affected thereby. If the proposed purchaser does not consummate the purchase of all of the shares
of Common Stock requested to be included in the Tag-Along Sale by any Tag-Along Stockholder on the same terms and conditions applicable to CuraGen, then CuraGen shall not consummate the Tag-Along Sale of any of its shares of Common Stock to such
purchaser, unless the shares of CuraGen and the Tag-Along Stockholders are reduced or limited pro rata in proportion to the respective number of shares of Common Stock actually sold in any such Tag-Along Sale and all other terms and
conditions of the Tag-Along Sale are the same for CuraGen and the Tag-Along Stockholders, subject to the provisions set forth in §7.01. 
  
 If a Tag-Along Notice from any Tag-Along Stockholder is not received by the party proposing the Tag-Along Sale prior to the 7 day period specified above,
then CuraGen shall have the right to consummate the Tag-Along Sale without the participation of such Tag-Along Stockholder, but only on terms and conditions which are no more favorable in any material respect to CuraGen (and in any event, at no
greater a purchase price) than as stated in the Tag-Along Sale Notice and only if such Tag-Along Sale occurs on a date within 90 days of the Tag-Along Sale Date. If such Tag-Along Sale does not occur within such 90 day period, the shares of Common
Stock that were to be subject to such Tag-Along Sale thereafter shall continue to be subject to all of the restrictions contained in this Agreement. 
  
 §7.04. Delivery of Certificates. On the Tag-Along Sale Date, each Tag-Along Stockholder shall deliver a certificate or certificates for
the shares of Common Stock to be sold in connection with the Tag-Along Sale, duly endorsed for transfer with signatures guaranteed, to the purchaser in the manner and at the address indicated in the Tag-Along Notice against delivery of immediately
available funds in the amount of the purchase price for such shares of Common Stock. 
  
 §7.05 Limitation on CuraGen Acquiring Capital Stock of the Company. CuraGen will not acquire in the aggregate more than [16.7% of CuraGen’s holdings] shares of Common Stock or any securities
convertible into (except for shares of Common Stock issuable upon conversion of the Series A Preferred Stock and Series B Preferred Stock outstanding on the date hereof and the Series C Preferred Stock or Series D Preferred Stock to issued pursuant
to the terms of this Agreement), or options, warrants, or rights to purchase, such shares of Common Stock (as adjusted for any stock dividends, stock splits, recapitalizations, consolidations or the like). 
  

 14 

 §7.06. Termination of Rights. The rights contained in this Section 7 shall terminate
and be of no further force or effect immediately prior to the earliest to occur of: 
  

	 	(a)	 	the effective date of the registration statement relating to an Initial Public Offering; or 

  

	 	(b)	 	the consummation of the sale of all, or substantially all, of the Company’s assets or capital stock, either through a direct sale, merger, reorganization, consolidation or
other form of business combination or acquisition in which the Company is the target of such acquisition and/or voting control of the equity securities of the Company is transferred to a third party unaffiliated with the Company.

  
 §7.07. Waiver of Other
Rights. Each of the Purchasers hereby waives for all time any and all rights it (or any of its successors) had or have under Section 8 (other than Section 8.05) of the Series B Purchase Agreement. 
  
 §8. MISCELLANEOUS 
  
 §8.01. Expenses. Each party hereto will pay its own
expenses in connection with the transactions contemplated hereby, whether or not such transactions shall be consummated. Notwithstanding the foregoing, the Company will pay the costs and expenses incurred by CuraGen in connection with the
transactions contemplated hereby. 
  
 §8.02. Survival
of Agreements. Regardless of any investigation made at any time by or on behalf of CuraGen or the Purchasers, all covenants, agreements, representations and warranties made herein or in an agreement, certificate or instrument delivered to
CuraGen and the Purchasers pursuant to or in connection with this Agreement, the Registration Rights Agreement or the Waiver Agreement, shall survive the execution and delivery of this Agreement, the Registration Rights Agreement and the Waiver
Agreement, the issuance, sale and delivery of the Series C Preferred Stock and Series D Preferred Stock, and the issuance and delivery of the Conversion Shares for an indefinite period of time (except for the representations and warranties contained
in Sections 2.03, 2.04, 2.06, 2.07, 2.08, 2.09, 2.10, 2.11, 2.12 and 2.13 hereof, which shall survive until the close of business on the date that is twenty-four (24) months from the date hereof, and the representations and warranties contained in
Section 2.05, which shall survive until the termination of the applicable statute of limitations), and all statements contained in any certificate or other instrument delivered by the Company hereunder or thereunder or in connection herewith or
therewith shall be deemed to constitute representations and warranties made by the Company. 
  
 §8.03. Brokerage. Each party hereto will indemnify and hold harmless the others against and in respect of any claim for brokerage, finder’s fees or other commissions relative to this Agreement
or to the transactions contemplated hereby, based in any way on agreements, arrangements or understandings made or claimed to have been made by such party with any third party. 
  
 §8.04. Parties in Interest. All representations, covenants and agreements contained in this Agreement by
or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and assigns of the parties hereto whether so expressed or not. Without limiting the generality of the foregoing, all representations,
covenants and agreements benefiting 

  

 15 

 
CuraGen and the Purchasers shall inure to the benefit of any and all subsequent holders from time to time of the Series C Preferred Stock, Series D Preferred
Stock or Conversion Shares. 
  
 §8.05. Notices.
All notices, requests, consents and other communications hereunder shall be in writing and shall be delivered in person or mailed by certified or registered mail, return receipt requested, or telexed or delivered by a recognized overnight carrier,
addressed as follows: 
  

	 	(a)	 	if to the Company, at 

  
 20 Commercial Street 
 Branford, CT 06405 
  

	 	(b)	 	if to CuraGen, at 

  
 555 Long Wharf Drive, 11th Floor 
 New Haven, Connecticut 06511 
  

	 	(c)	 	if to any Purchaser, at the address of such Purchaser set forth in Schedule 1; 

  
 or, in any such case, at such other address or addresses as shall have been furnished in writing by such party to the others. 
  
 §8.06. Governing Law. This Agreement shall be governed by
and construed in accordance with the laws of the State of Delaware. 
  
 §8.07. Entire Agreement. This Agreement, including the Schedules and Exhibits hereto, constitutes the sole and entire agreement of the parties with respect to the subject matter hereof. All Schedules and Exhibits hereto
are hereby incorporated herein by reference. 
  
 §8.08.
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 §8.09. Amendments and Waivers. This Agreement may be
amended or modified, and provisions hereof may be waived, with the written consent of the Company, CuraGen and the holders of at least two-thirds (2/3) of the outstanding Series D Preferred Stock, except for any amendment, modification or waiver
which adversely affects the rights of the holders of the Series D Preferred Stock, in which case written consent of 100% of the holders of the outstanding Series D Preferred Stock shall be required. 
  
 §8.10. Severability. If any provision of this Agreement
shall be declared void or unenforceable by any judicial or administrative authority, the validity of any other provision and of the entire Agreement shall not be affected thereby. 
  

 16 

 §8.11. Titles and Subtitles. The titles and subtitles used in this Agreement are for
convenience only and are not to be considered in construing or interpreting any term or provision of this Agreement. 
  
 §8.12. Certain Defined Terms. As used in this Agreement, the following terms shall have the following meanings (such meanings to be
equally applicable to both the singular and plural forms of the terms defined): 
  
 (a) “person” shall mean an individual, corporation, trust, partnership, joint venture, unincorporated organization,
government agency or any agency or political subdivision thereof, or other entity. 
  
 (b) “subsidiary” shall mean, as to the Company, any corporation, limited liability company or other entity of which more
than 50% of the outstanding stock having ordinary voting power to elect a majority of the Board of Directors of such corporation (irrespective of whether or not at the time stock of any other class or classes of such corporation shall have or might
have voting power by reason of the happening of any contingency) is at the time directly or indirectly owned by the Company, or by one or more of its subsidiaries, or by the Company and one or more of its subsidiaries. 
  

 17 

 IN WITNESS WHEREOF, the Company, CuraGen and the Purchasers have executed this Agreement as of the
day and year first above written. 
  

					
	454 Corporation
		
	 By:
	 	 /s/    Richard F. Begley, Ph.D.

	 	 	 Name:
	 	Richard F. Begley, Ph.D.
	 	 	 Title:
	 	Chief Executive Officer and President

  

					
	CuraGen Corporation
		
	 By:
	 	 /s/    Jonathan M. Rothberg

	 	 	 Name:
	 	Jonathan M. Rothberg
	 	 	 Title:
	 	Chief Executive Officer and President

  

	
	PURCHASERS:
	
	/s/    Michael J. Rothberg
	

	Michael J. Rothberg
	
	/s/    Jonathan M. Rothberg
	

	Jonathan M. Rothberg
	
	/s/    Gianpiero Molinari
	

	Gianpiero Molinari
	
	/s/    Henry B. Rothberg
	

	Henry B. Rothberg
	
	/s/    David A. Rothberg
	

	David A. Rothberg
	
	/s/    Celia R. Meadow
	

	Celia R. Meadow

  

	
	
	/s/    Deborah J. Rothberg
	

	Deborah J. Rothberg
	
	/s/    Judith Rothberg
	

	Judith Rothberg
	
	/s/    Bonnie E. Rothberg
	

	Bonnie E. Rothberg
	
	/s/    Gioel Molinari
	

	Gioel Molinari
	
	/s/    Jason Molinari
	

	Jason Molinari
	
	/s/    Micol Molinari
	

	Micol Molinari
	
	/s/    Henry B. Rothberg
	

	Henry B. Rothberg, as Custodian for Alex Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Henry B. Rothberg
	

	Henry B. Rothberg, as Custodian for Rebecca Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Henry B. Rothberg
	

	Henry B. Rothberg, as Custodian for Samantha Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    David A. Rothberg
	

	David A. Rothberg, as Custodian for Daniel B. Rothberg under the Connecticut Uniform Transfers to Minors Act

  

	
	
	/s/    David A. Rothberg
	

	David A. Rothberg, as Custodian for Jason B. Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Deborah J. Rothberg
	

	Deborah J. Rothberg, as Custodian for Analise Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Celia R. Meadow
	

	Celia R. Meadow, as Custodian for Simone Meadow under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Celia R. Meadow
	

	Celia R. Meadow, as Custodian for Averill Meadow under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Celia R. Meadow
	

	Celia R. Meadow, as Custodian for Herschel Meadow under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Jonathan M. Rothberg
	

	Jonathan M. Rothberg, as Custodian for Jordana Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Jonathan M. Rothberg
	

	Jonathan M. Rothberg, as Custodian for Noah Rothberg under the Connecticut Uniform Transfers to Minors Act

  

	
	
	/s/    Jonathan M. Rothberg
	

	Jonathan M. Rothberg, as Custodian for Elana Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Michael J. Rothberg
	

	Michael J. Rothberg, as Custodian for Andrew Rothberg under the Florida Uniform Transfers to Minors Act
	
	/s/    Michael J. Rothberg
	

	Michael J. Rothberg, as Custodian for Justin Rothberg under the Florida Uniform Transfers to Minors Act
	
	/s/    Robert E. Patricelli
	

	Robert E. Patricelli

  

			
	Henry M. Rothberg, Lillian R. Rothberg, and Michael J. Rothberg, as Trustees of the Henry M. Rothberg Family Trust u/i/d 12/4/00
	
	BY TRUSTEES:
		
	 	 	 /s/    Henry M. Rothberg

	 	 	Henry M. Rothberg, Trustee
		
	 	 	 /s/    Lillian R. Rothberg

	 	 	Lillian R. Rothberg, Trustee
		
	 	 	 /s/    Michael J. Rothberg

	 	 	Michael J. Rothberg, Trustee

  

			
	Lillian R. Rothberg, Henry M. Rothberg, and Michael J. Rothberg, as Trustees of the Lillian R. Rothberg Family Trust u/i/d 12/4/00
	
	BY TRUSTEES:
		
	 	 	 /s/    Lillian R. Rothberg

	 	 	Lillian R. Rothberg, Trustee
		
	 	 	 /s/    Henry M. Rothberg

	 	 	Henry M. Rothberg, Trustee
		
	 	 	 /s/    Michael J. Rothberg

	 	 	Michael J. Rothberg, Trustee

  

					
	Jonathan M. Rothberg Family Limited Partnership
		
	 	 	 /s/    Jonathan M. Rothberg

	 	 	 By:
	 	Jonathan M. Rothberg
	 	 	 Its:
	 	Its General Partner

  

			
	MFIC LLC
		
	 By:
	 	 /s/    Chris McLeod

	 Name:
	 	Chris McLeod
	 Title:
	 	Manager

  

			
	Mintz Levin Investments LLC
		
	 By:
	 	  

	 Name:
	 	 
	 Title:
	 	 

  

			
	Quantum Industrial Partners LDC
		
	 By:
	 	 *

	 Name:
	 	 
	 Title:
	 	 

  
 * Not a purchaser 
  

			
	Quantum Partners LDC
		
	 By:
	 	 *

	 Name:
	 	 
	 Title:
	 	 

  

			
	CLSP, L.P.
	By:	 	 Cooper Hill Partners, LLC
 its General
Partner

		
	 By:
	 	 /s/    Jeffrey W. Casdin

	 Name:
	 	Jeffrey W. Casdin
	 Title:
	 	CEO

  

			
	CLSP-SBS I, L.P.
	By:	 	 Cooper Hill Partners, LLC
 its General
Partner

		
	 By:
	 	 /s/    Jeffrey W. Casdin

	 Name:
	 	Jeffrey W. Casdin
	 Title:
	 	CEO

  

			
	CLSP-SBS II, L.P.
	By:	 	 Cooper Hill Partners, LLC
 its General
Partner

		
	 By:
	 	 /s/    Jeffrey W. Casdin

	 Name:
	 	Jeffrey W. Casdin
	 Title:
	 	CEO

  

			
	CLSP II, L.P.
	By:	 	 Cooper Hill Partners, LLC
 its General
Partner

		
	 By:
	 	 /s/    Jeffrey W. Casdin

	 Name:
	 	Jeffrey W. Casdin
	 Title:
	 	CEO

  
 * Not a purchaser 
  

 EXECUTION COPY 
  
 WAIVER AND 
 AMENDMENT NO. 1 TO PURCHASE AGREEMENT 
  
 WAIVER AND AMENDMENT NO. 1 TO PURCHASE AGREEMENT (“Waiver and Amendment No. 1”) dated as of September 18, 2003, among 454 Corporation, a Delaware corporation (the “Company”), CuraGen Corporation, a Delaware
corporation (“CuraGen”), and the several purchasers named in the attached Schedule 1 (individually, a “Purchaser” and collectively the “Purchasers”). 
  
 WHEREAS, the Company, CuraGen and certain purchasers entered into a Purchase Agreement (the “Purchase
Agreement”) dated as of June 5, 2000 in connection with the issuance by the Company of Units (as defined in the Purchase Agreement); and 
  
 WHEREAS, in order to facilitate the proposed issuance by the Company of shares of Series C Preferred Stock and Series D Preferred Stock, pursuant
to a purchase agreement dated the date hereof among the Company, CuraGen and certain purchasers (the “Proposed Financing”), the Company and the other parties hereto desire to waive and modify Section 8.05 of the Purchase Agreement in
accordance with the provisions of the Purchase Agreement. 
  
 NOW, THEREFORE, IT IS AGREED: 
  
 Section 1.
Waiver of Section 8.05 of the Purchase Agreement. The undersigned hereby waive the application of the restrictions set forth in Section 8.05 of the Purchase Agreement to the Proposed Financing. 
  
 Section 2. Amendment of Section 8.01(a) of the Purchase Agreement.
Section 8.01(a) of the Purchase Agreement is hereby deleted in its entirety and replaced with the following: 
  
 (a) Opportunity to Participate. If CuraGen proposes to enter into an agreement to sell or otherwise dispose of for value (such sale or other
disposition for value being referred to as a “Tag-Along Sale”) more than 3,073,611 shares (as adjusted for any stock dividends, stock splits, recapitalizations, consolidations or the like) of Common Stock in a single or series of
transactions, then CuraGen shall afford the holders of shares of the Series B Preferred Stock the opportunity to participate proportionately in such Tag-Along Sale (the person(s) being afforded the opportunity to participate proportionately in such
Tag-Along Sale being referred to as the “Tag-Along Stockholders”) in accordance with this Section 8. For purposes of this Section 8, the term “Common Stock” shall include shares of Common Stock issuable upon the conversion of
securities convertible into Common Stock. 

 Section 3. Amendment of Section 8.05 of the Purchase Agreement. Section 8.05 of the Purchase
Agreement is hereby deleted in its entirety and replaced with the following: 
  
 §8.05 Limitation on CuraGen Acquiring Capital Stock of the Company. CuraGen will not acquire in the aggregate more than 3,073,611 shares of Common Stock or any securities convertible into (except
for shares of Common Stock issuable upon conversion of the Series A Preferred Stock and the Series B Preferred Stock outstanding on the date hereof and any Series C Preferred Stock of the Company or any Series D Preferred Stock of the Company to be
issued pursuant to a purchase agreement dated September 18, 2003 among the Company, CuraGena and certain purchasers), or options, warrants, or rights to purchase, such shares of Common Stock (as adjusted for any stock dividends, stock splits,
recapitalizations, consolidations or the like). 
  
 Section 4.
Further Assurances. Each party hereby agrees, at any time and from time to time after the date hereof, at the reasonable request of the other parties, to execute and deliver such other agreements, certificates or instruments as may be
reasonably requested in order to more effectively amend the Purchase Agreement as set forth above or to confirm this Waiver and Amendment No. 1. 
  
 Section 5. Effect of Waiver and Amendment. The parties hereby ratify and confirm all of the provisions of the Purchase Agreement, as modified
hereby, and agree and acknowledge that the same as so amended remains in full force and effect. 
  
 Section 6. Governing Law. This Waiver and Amendment No. 1 shall be governed by and construed in accordance with the laws of the State of Delaware.

  
 Section 7. Counterparts. This Waiver and Amendment No.
1 may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 [THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the Company, CuraGen and the Purchasers have executed this Waiver and
Amendment No. 1 as of the day and year first above written. 
  

					
	454 Corporation
		
	 By:
	 	 /s/    Richard F. Begley, Ph.D.

	 	 	 Name:
	 	Richard F. Begley, Ph.D.
	 	 	 Title:
	 	Chief Executive Officer and President

  

					
	CuraGen Corporation
		
	 By:
	 	 /s/    Jonathan M. Rothberg

	 	 	 Name:
	 	Jonathan M. Rothberg
	 	 	 Title:
	 	Chief Executive Officer and President

  

	
	 PURCHASERS:

	
	/s/    Michael J. Rothberg
	

	Michael J. Rothberg
	
	/s/    Jonathan M. Rothberg
	

	Jonathan M. Rothberg
	
	/s/    Gianpiero Molinari
	

	Gianpiero Molinari
	
	/s/    Henry B. Rothberg
	

	Henry B. Rothberg
	
	/s/    David A. Rothberg
	

	David A. Rothberg
	
	/s/    Celia R. Meadow
	

	Celia R. Meadow

	
	
	/s/    Deborah J. Rothberg
	

	Deborah J. Rothberg
	
	/s/    Judith Rothberg
	

	Judith Rothberg
	
	/s/    Bonnie E. Rothberg
	

	Bonnie E. Rothberg
	
	/s/    Gioel Molinari
	

	Gioel Molinari
	
	/s/    Jason Molinari
	

	Jason Molinari
	
	/s/    Micol Molinari
	

	Micol Molinari
	
	/s/    Henry B. Rothberg
	

	Henry B. Rothberg, as Custodian for Alex Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Henry B. Rothberg
	

	Henry B. Rothberg, as Custodian for Rebecca Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Henry B. Rothberg
	

	Henry B. Rothberg, as Custodian for Samantha Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    David A. Rothberg
	

	David A. Rothberg, as Custodian for Daniel B. Rothberg under the Connecticut Uniform Transfers to Minors Act

	
	
	/s/    David A. Rothberg
	

	David A. Rothberg, as Custodian for Jason B. Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Deborah J. Rothberg
	

	Deborah J. Rothberg, as Custodian for Analise Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Celia R. Meadow
	

	Celia R. Meadow, as Custodian for Simone Meadow under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Celia R. Meadow
	

	Celia R. Meadow, as Custodian for Averill Meadow under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Celia R. Meadow
	

	Celia R. Meadow, as Custodian for Herschel Meadow under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Jonathan M. Rothberg
	

	Jonathan M. Rothberg, as Custodian for Jordana Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Jonathan M. Rothberg
	

	Jonathan M. Rothberg, as Custodian for Noah Rothberg under the Connecticut Uniform Transfers to Minors Act

	
	
	/s/    Jonathan M. Rothberg
	

	Jonathan M. Rothberg, as Custodian for Elana Rothberg under the Connecticut Uniform Transfers to Minors Act
	
	/s/    Michael J. Rothberg
	

	Michael J. Rothberg, as Custodian for Andrew Rothberg under the Florida Uniform Transfers to Minors Act
	
	/s/    Thomas R. Patricelli
	

	Thomas R. Patricelli
	
	/s/    Alison J. Patricelli
	

	Alison J. Patricelli

  

			
	Henry M. Rothberg, Lillian R. Rothberg, and Michael J. Rothberg, as Trustees of the Henry M. Rothberg Family Trust u/i/d 12/4/00
	
	 BY TRUSTEES:

		
	 	 	/s/    Henry M. Rothberg
	 	 	

	 	 	Henry M. Rothberg, Trustee
		
	 	 	/s/    Lillian R. Rothberg
	 	 	

	 	 	Lillian R. Rothberg, Trustee
		
	 	 	/s/    Michael J. Rothberg
	 	 	

	 	 	Michael J. Rothberg, Trustee

			
	Lillian R. Rothberg, Henry M. Rothberg, and Michael J. Rothberg, as Trustees of the Lillian R. Rothberg Family Trust u/i/d 12/4/00
	
	 BY TRUSTEES:

		
	 	 	/s/    Lillian R. Rothberg
	 	 	

	 	 	Lillian R. Rothberg, Trustee
		
	 	 	/s/    Henry M. Rothberg
	 	 	

	 	 	Henry M. Rothberg, Trustee
		
	 	 	/s/    Michael J. Rothberg
	 	 	

	 	 	Michael J. Rothberg, Trustee

  

					
	Jonathan M. Rothberg Family Limited Partnership
		
	 	 	/s/    Jonathan M. Rothberg
	 	 	

	 	 	 By:
	 	Jonathan M. Rothberg
	 	 	 Its:
	 	Its General Partner

  

			
	MFIC LLC
		
	 By:
	 	/s/    Chris Mcleod        
	 	 	

	 Name:
	 	Chris Mcleod
	 Title:
	 	Manager

  

			
	Mintz Levin Investments LLC
		
	 By:
	 	 
	 	 	

	 Name:
	 	 
	 Title:
	 	 

  

			
	Quantum Industrial Partners LDC
		
	 By:
	 	*
	 	 	

	 Name:
	 	 
	 Title:
	 	 

			
	Quantum Partners LDC
		
	 By:
	 	*
	 	 	

	 Name:
	 	 
	 Title:
	 	 

  

			
	CLSP, L.P.
	By:	 	 Cooper Hill Partners, LLC
 its General
Partner

		
	 By:
	 	/s/    Jeffrey W. Casdin
	 	 	

	 Name:
	 	Jeffrey W. Casdin
	 Title:
	 	CEO

  

			
	CLSP-SBS I, L.P.
	By:	 	 Cooper Hill Partners, LLC
 its General
Partner

		
	 By:
	 	/s/    Jeffrey W. Casdin
	 	 	

	 Name:
	 	Jeffrey W. Casdin
	 Title:
	 	CEO

  

			
	CLSP-SBS II, L.P.
	By:	 	 Cooper Hill Partners, LLC
 its General
Partner

		
	 By:
	 	/s/    Jeffrey W. Casdin
	 	 	

	 Name:
	 	Jeffrey W. Casdin
	 Title:
	 	CEO

  

			
	CLSP II, L.P.
	By:	 	 Cooper Hill Partners, LLC
 its General
Partner

		
	 By:
	 	/s/    Jeffrey W. Casdin
	 	 	

	 Name:
	 	Jeffrey W. Casdin
	 Title:
	 	CEOAMENDED AND RESTATED TECHNOLOGY TRANSFER AND LICENCE AGREEMENT

 EXHIBIT 10.27 
  
 AMENDED AND RESTATED TECHNOLOGY TRANSFER AND LICENSE 
 AGREEMENT 
  
 by and between 
  
 CURAGEN CORPORATION

  
 and 
  
 454 CORPORATION 
  
 June 24, 2003 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 

 TABLE OF CONTENTS 
  

					
	 	  	Page

		
	 ARTICLE 1. DEFINITIONS
	  	1
	 1.1
	  	 AFFILIATE
	  	1
	 1.2
	  	 BETA SITE AGREEMENT
	  	2
	 1.3
	  	 CONFIDENTIAL INFORMATION
	  	2
	 1.4
	  	 “CONTROL” OR “CONTROLLED”
	  	2
	 1.5
	  	 CORE KNOW-HOW
	  	2
	 1.6
	  	 CORE PATENT RIGHTS
	  	2
	 1.7
	  	 CORE TECHNOLOGY
	  	2
	 1.8
	  	 CURAGEN FIELD
	  	2
	 1.9
	  	 CURAGEN PROCESS IMPROVEMENT
	  	3
	 1.10
	  	 CURAGEN PROPRIETARY SOFTWARE
	  	3
	 1.11
	  	 “CURAGEN THIRD PARTY PROCESS
IMPROVEMENT”
	  	3
	 1.12
	  	 “EFFECTIVE DATE”
	  	3
	 1.13
	  	 FIRST COMMERCIAL SALE
	  	3
	 1.14
	  	 454 FIELD
	  	3
	 1.15
	  	 454 PROCESS IMPROVEMENTS
	  	3
	 1.16
	  	 “454 THIRD PARTY PROCESS IMPROVEMENT”
	  	3
	 1.17
	  	 “INSTRUMENT”
	  	3
	 1.18
	  	 “NET SALES”
	  	3
	 1.19
	  	 “NON-COMPETITION PERIOD”
	  	4
	 1.20
	  	 “OTHER FIELDS”
	  	4
	 1.21
	  	 “REAGENTS”
	  	4
	 1.22
	  	 “ROYALTY-BEARING SERVICES”
	  	4
	 1.23
	  	 “SEQUENCING SERVICES”
	  	4
	 1.24
	  	 “SOFTWARE”
	  	4
	 1.25
	  	 SOFTWARE LICENSE AGREEMENT
	  	4
	 1.26
	  	 “TECHNOLOGY”
	  	5
	 1.27
	  	 “THIRD PARTY”
	  	5
		
	 ARTICLE 2. TECHNOLOGY TRANSFER
	  	5
	 2.1.
	  	 GRANT OF RIGHTS TO 454
	  	 
	 2.1.1
	  	 Scope of Technology License
	  	5
	 2.1.2
	  	 Retained Rights of CuraGen
	  	5
	 2.1.3
	  	 Royalties
	  	5
	 2.1.4
	  	 CuraGen Process Improvements
	  	6
	 2.1.5
	  	 CuraGen Third Party Process Improvements
	  	6
	 2.1.6
	  	 Grant of Software License to 454
	  	6
	 2.1.7
	  	 Non-Competition in CuraGen Field
	  	6
	 2.1.8
	  	 Consideration for the Grant of Rights
	  	7
	 2.2.
	  	 GRANT OF RIGHTS TO CURAGEN
	  	7
	 2.2.1.
	  	 Grant of Technology License
	  	7
	 2.2.2.
	  	 Grant of Beta Test License
	  	8
	 2.2.3.
	  	 Supply of Instruments and Reagents
	  	8
	 2.3.
	  	 RIGHTS IN OTHER FIELDS
	  	9
	 2.3.1.
	  	 Rights in Other Fields
	  	9
	 2.3.2.
	  	 Right of First Negotiation
	  	9
	 2.4.
	  	 CORPORATE OPPORTUNITY
	  	9
	 2.5
	  	 ROYALTIES ON SALES OF ROYALTY-BEARING
SERVICES
	  	10
	 2.5.1
	  	 Royalties; Accounting
	  	10
	 2.5.2
	  	 Third Party Royalty Offset
	  	10

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 i 

					
	 2.5.3
	  	 Royalty Term
	  	10
	 2.5.4
	  	 Payment Terms
	  	10
	 2.5.5
	  	 Overdue Royalties
	  	11
	 2.5.6
	  	 Records Retention; Review
	  	12
	 2.6
	  	 EARLY ACCESS TO ROYALTY-BEARING
SERVICES
	  	12
	 2.7
	  	 APPROVAL OF CERTAIN CONTRACTS
	  	12
	 2.8
	  	 SALES TO HUMAN HEALTH CARE
COMPANIES
	  	13
	 2.9
	  	 SEQUENCING SERVICES FOR CURAGEN
	  	13
		
	 ARTICLE 3. LIMITATION OF LIABILITY
	  	13
	 3.1.
	  	 CURAGEN LIMITATION OF LIABILITY AND
RIGHT TO INDEMNIFICATION
	  	13
	 3.2.
	  	 454 LIMITATION OF LIABILITY AND RIGHT TO
INDEMNIFICATION
	  	13
	 3.3.
	  	 INDEMNIFICATION PROCEDURES
	  	14
		
	 ARTICLE 4. TREATMENT OF CONFIDENTIAL INFORMATION
	  	14
	 4.1.
	  	 CONFIDENTIAL INFORMATION
	  	14
	 4.2.
	  	 REPRESENTATION
	  	14
	 4.3.
	  	 PROPRIETARY MATERIALS
	  	15
	 4.4.
	  	 PUBLICITY
	  	15
		
	 ARTICLE 5. REPRESENTATIONS AND WARRANTIES
	  	15
	 5.1.
	  	 REPRESENTATIONS, WARRANTIES AND COVENANTS OF
CURAGEN
	  	15
	 5.2.
	  	 REPRESENTATIONS, WARRANTIES AND COVENANTS OF 454
	  	16
		
	 ARTICLE 6. PATENT PROSECUTION AND INFRINGEMENT
	  	16
	 6.1.
	  	 RIGHTS IN THE CORE TECHNOLOGY
	  	16
	 6.2.
	  	 PATENT COORDINATORS
	  	17
	 6.3.
	  	 NOTIFICATION OF INFRINGEMENT OR BREACH
	  	17
	 6.4.
	  	 ENFORCEMENT OF RIGHTS IN THE CORE
TECHNOLOGY
	  	17
	 6.5.
	  	 RIGHTS IN IMPROVEMENT
	  	18
	 6.6.
	  	 LIMITATION ON WARRANTIES
	  	18
	 6.7.
	  	 LIMITATION ON DAMAGES
	  	18
		
	 ARTICLE 7. TERM
	  	18
	 7.1.
	  	 TERM
	  	18
	 7.2.
	  	 TERMINATION
	  	18
	 7.2.1.
	  	 Right to Terminate
	  	18
	 7.2.2.
	  	 Bankruptcy
	  	18
	 7.2.3.
	  	 Surviving Provisions
	  	19
		
	 ARTICLE 8. MISCELLANEOUS
	  	19
	 8.1.
	  	 NOTICES
	  	19
	 8.2.
	  	 ENTIRE AGREEMENT
	  	19
	 8.3.
	  	 NO IMPLIED WAIVERS: RIGHTS CUMULATIVE
	  	20
	 8.4.
	  	 AMENDMENTS
	  	20
	 8.5.
	  	 SUCCESSORS AND ASSIGNS
	  	20
	 8.6.
	  	 GOVERNING LAW
	  	20
	 8.7.
	  	 FORCE MAJEURE
	  	20
	 8.8.
	  	 FURTHER ASSURANCES
	  	20
	 8.9.
	  	 SEVERABILITY
	  	20
	 8.10.
	  	 HEADINGS
	  	21
	 8.11.
	  	 INTERPRETATION
	  	21
	 8.12.
	  	 EXECUTION IN COUNTERPARTS
	  	21
	 8.13.
	  	 TERMINATION OF ORIGINAL AGREEMENT
	  	21

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 ii 

			
		
	 SCHEDULE A - CORE PATENT RIGHTS
	  	23
		
	 SCHEDULE B - THIRD PARTY ROYALTIES
	  	24
		
	 SCHEDULE C - TERMS OF SUPPLY OF INSTRUMENTS, REAGENTS AND SOFTWARE
	  	25
		
	 SCHEDULE D - PROMOTION OF SEQUENCING SERVICES
	  	26
		
	 EXHIBIT A - FORM OF SOFTWARE LICENSE AGREEMENT
	  	27
		
	 EXHIBIT B - FORM OF BETA SITE AGREEMENT
	  	28

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 iii 

 AMENDED AND RESTATED 
 TECHNOLOGY TRANSFER AND LICENSE AGREEMENT 
  
 THIS AMENDED AND RESTATED TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (this “Agreement”) is dated as of June 24, 2003 (the “Restated Effective Date”) and is made by and between CuraGen
Corporation, a Delaware corporation (“CuraGen”), and 454 Corporation, a Delaware corporation (“454”). 
  
 RECITALS 
  
 WHEREAS, 454 was formed to develop and exploit certain technology, methods and software developed at CuraGen for DNA-based analysis; and 
  
 WHEREAS, pursuant to the terms of the Technology Transfer and License
Agreement dated as of June 6, 2000 by and between CuraGen and 454 (the “Original Agreement”), CuraGen exclusively licensed to 454 certain technology related to DNA-based analysis and certain improvements to such technology made
and/or obtained by CuraGen for 454 to design, produce and sell equipment, instrumentation and reagents for DNA-based analysis in the 454 Field (as defined below) and 454 granted to CuraGen certain preferential access to such instrumentation,
reagents and technology and certain improvements to such technology made by 454 for CuraGen to use in the CuraGen Field (as defined below); and 
  
 WHEREAS, the parties hereto wish to amend the Original Agreement to, inter alia, expand the permissible activities contemplated by the 454
Field, and to provide for the payment of a royalty by 454 to CuraGen in connection with 454’s providing of certain Sequencing Services (as defined below) and; 
  
 WHEREAS, the parties wish to set forth in a single document the terms and conditions of the Original Agreement, as so
amended. 
  
 NOW, THEREFORE, in consideration of the mutual
covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, CuraGen and 454 agree as follows: 
  
 ARTICLE 1. DEFINITIONS 
  
 All capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth below. 
  
 1.1 “Affiliate” means any corporation, firm, limited
liability company, partnership or other entity which directly or indirectly controls or is controlled by or is under common control with a party. For purposes of this Section 1.1 of this Agreement, “control” means ownership,
directly or through one or more Affiliates, of more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or more than fifty percent (50%) of the equity interests in the case of
any other type of legal entity, status as a 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 

 
general partner in any partnership, or any other arrangement whereby a party controls or has the right to control the Board of Directors or equivalent
governing body of a corporation or other entity. 
  
 1.2
“Beta Site Agreement” has the meaning set forth in Section 2.2.2. 
  
 1.3 “Confidential Information” means the Core Technology and the prosecution files pertaining to the Core Patent Rights (both of which shall be deemed to be Confidential Information of 454), all
proprietary information of 454, including 454’s business plans, mission, vision, specific technology, employees, advisors and consultants, all information concerning the terms of this Agreement and any other information which is disclosed by
one party (the “disclosing party”) to the other party (the “receiving party”) pursuant to this Agreement. Notwithstanding the foregoing, Confidential Information shall not include information which: (a) is available to the public
at the time of disclosure or becomes publicly known through no breach by the receiving party of the undertakings hereunder; (b) is disclosed, without restriction on further disclosure or use to the receiving party by a Third Party having a lawful
right to make such disclosure; (c) the receiving party can establish by reasonable proof was in its possession at the time of disclosure or was subsequently and independently developed by employees of the receiving party who had no knowledge of the
information disclosed; (d) is reasonably necessary to file or prosecute patent applications, to apply for regulatory approval to test or market products or services, or to prosecute or defend litigation so long as the receiving party uses reasonable
efforts to secure confidential treatment when available; or (e) is approved for release by written authorization of the disclosing party. Notwithstanding the foregoing, the exception set forth in clause (c) above shall not apply to the Core
Technology or the prosecution files pertaining to the Core Patent Rights. 
  
 1.4 “Control” or “Controlled” means with respect to any Technology, the possession by a party of the ability to grant a license or sublicense of such Technology as provided herein
without violating the terms of any agreement or arrangement between such party and any Third Party. 
  
 1.5 “Core Know-How” means Technology Controlled by CuraGen as of the Effective Date relating to the use of any invention claimed in the
Core Patent Rights. 
  
 1.6 “Core Patent Rights”
means the provisional patent applications owned in whole or in part by CuraGen on the Effective Date that are listed on Schedule A attached hereto; any patent claims filed by CuraGen claiming inventions included in such provisional patent
applications; patents issuing from such patent claims; and all divisionals, continuations, continuations-in-part (but solely to the extent directed to claims included in such provisional patent applications), divisions and renewals, all letters
patent granted thereon, and all reissues, reexaminations and extensions thereof. 
  
 1.7 “Core Technology” means the Core Know-How and Core Patent Rights. 
  
 1.8 “CuraGen Field” means [****************************************************************************] 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 2 

 1.9 “CuraGen Process Improvement” means any Technology conceived or reduced to practice
by CuraGen during the term of this Agreement which is covered by a claim of the Core Patent Rights. 
  
 1.10 “CuraGen Proprietary Software” has the meaning set forth in the Software License Agreement. 
  
 1.11 “CuraGen Third Party Process Improvement” means any
Technology (a) that is conceived or developed by any Third Party, (b) for which rights become Controlled by CuraGen at any time during the term of this Agreement and (c) that would constitute a CuraGen Process Improvement if it had been conceived or
reduced to practice by CuraGen during such time period. 
  
 1.12
“Effective Date” means June 6, 2000, the Effective Date of the Original Agreement. 
  
 1.13 “First Commercial Sale” means the date of the first commercial sale (other than for purposes of obtaining regulatory approval or for
purposes of conducting preliminary testing) of any Royalty-Bearing Service by or on behalf of 454 to a Third Party in an arms-length transaction. 
  
 1.14 “454 Field” means (a) [************************************************************************** 
 *******************************] and (b) [*************************]. 
  
 1.15 “454 Process Improvement” means any Technology conceived or reduced to practice by 454 during the term of this Agreement which is
covered by a claim of the Core Patent Rights. 
  
 1.16
“454 Third Party Process Improvement” means any Technology (a) that is conceived or developed by any Third Party, (b) for which rights become Controlled by 454 at any time during the term of this Agreement period and (c) that would
be a 454 Process Improvement if it had been conceived or reduced to practice by 454 during such time period. 
  
 1.17 “Instrument” means any device, equipment or instrument covered by a claim under the Core Patent Rights which is used to conduct DNA
sequencing and/or analyze the results of such DNA sequencing, including, without limitation, the correlation of gene sequence expression and variation with disease, drug response or prognosis. 
  
 1.18 “Net Sales” means as to each calendar quarter during
the Term, the gross invoiced sales prices charged by or on behalf of 454 or its Affiliates or sublicensees on all sales of Royalty-Bearing Services to a Third Party, less the following amounts: 
  
 (a) trade, quantity and cash discounts actually allowed;

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 3 

 (b) discounts, refunds, rebates, chargebacks, retroactive price adjustments, billing
errors and any other allowances (including, without limitation, government-mandated and managed health care-negotiated rebates) actually granted which effectively reduce the net selling price; 
  
 (c) product returns, refunds, credits and allowances
actually granted; 
  
 (d) any sales and other
taxes or duties imposed on the sale or delivery of the Royalty-Bearing Service (excluding any taxes based on income); and 
  
 (e) freight, postage, packing, shipping, customs duties, excises, tariffs, surcharges, other governmental charges (excluding federal,
state or local taxes based on income or franchise taxes) and insurance charges actually allowed or paid for delivery of the Royalty-Bearing Service. 
  
 Such amounts shall be determined from the books and records of 454 and maintained in accordance with the generally accepted accounting principles,
consistently applied. For purposes of clarity, any upfront fee or periodic subscription fees charged by 454 in exchange for Royalty-Bearing Services in exchange for the right to commercially exploit Royalty-Bearing Services are specifically included
in Net Sales. 
  
 1.19 “Non-Competition Period”
means a period of [********] years; provided, that, if CuraGen terminates this Agreement in accordance with Section 7.2.1 of this Agreement, the Non-Competition Period means a period of [********] years. 
  
 1.20 “Other Fields” means all fields other than the CuraGen
Field and the 454 Field. 
  
 1.21 “Reagents”
means any chemical compound or mixture of chemical compounds covered by a claim under the Core Patent Rights developed for use in an Instrument. 
  
 1.22 “Royalty-Bearing Services” means the provision by 454 to any Third Party of [***********************]. 
  
 1.23 “Sequencing Services” means the use of Instruments to
[***********************************]. 
  
 1.24
“Software” means any computer programs and software covered by a claim under the Core Patent Rights developed for use on an Instrument, including any upgrades, modifications and enhancements made for such programs and software. For
purposes of this Agreement the term “Software” shall not indicate CuraGen Proprietary Software. 
  
 1.25 “Software License Agreement“ has the meaning set forth in Section 2.1.6. 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 4 

 1.26 “Technology” means and includes all inventions, discoveries, data, formulations,
techniques and know-how, whether or not patentable or copyrightable, including any Instruments. 
  
 1.27 “Third Party” means any entity other than CuraGen and 454 and their respective Affiliates. 
  
 ARTICLE 2. TECHNOLOGY TRANSFER 
  
 2.1. Grant of Rights to 454. 
  
 2.1.1. Scope of Technology License. Subject to the
terms and conditions of this Agreement, CuraGen hereby grants to 454 and its Affiliates a perpetual, exclusive (even as to CuraGen, except as provided in Section 2.1.2 and 2.2.1 of this Agreement), worldwide license or sublicense (as the case may
be), with the right to grant sublicenses, under CuraGen’s interest in the Core Technology, any CuraGen Process Improvements and any CuraGen Third Party Process Improvements (which, in the last case, 454 elects to license pursuant to Section
2.1.5 of this Agreement) (a) to make, have made, use, sell, have sold, import, and have imported Instruments, Reagents and Software and to provide Sequencing Services, in any case solely within the 454 Field and (b) to otherwise exploit the Core
Technology, CuraGen Process Improvements and such CuraGen Third Party Process Improvements, in each case for all purposes solely within the 454 Field. The foregoing licenses to 454 under the Core Technology shall be terminable by CuraGen only in
accordance with Section 7.2 of this Agreement. 
  
 2.1.2. Retained Rights of CuraGen. Notwithstanding anything to the contrary in Section 2.1.1 above, 454 hereby acknowledges and agrees that no license is granted to 454 and its Affiliates under this Agreement to exploit the Core
Technology, CuraGen Process Improvements and the CuraGen Third Party Process Improvements for any purpose outside the 454 Field. 
  
 2.1.3. Royalties. The licenses from CuraGen to 454 set forth in Section 2.1.1 of this Agreement shall be royalty-free and without a
duty of accounting on the part of 454 to CuraGen except (a) to the extent that fees, milestones, royalties or other payments are due to an entity other than CuraGen or 454 or a wholly-owned subsidiary of CuraGen or 454 (“Third Party
Royalties”) on account of 454’s exploitation of such license and (b) as provided in Section 2.5 below with respect to Royalty-Bearing Services. All such Third Party Royalties known to CuraGen as of the Effective Date are described on
Schedule B attached hereto. Unless otherwise required by the Third Party, 454 hereby agrees, with respect to all Core Technology and CuraGen Process Improvements and all CuraGen Third Party Process Improvements it licenses from CuraGen under
this Agreement, to pay all such Third Party Royalties and provide all related reports directly to the appropriate Third Parties within the time periods specified by the pertinent agreements with such Third Parties. CuraGen shall have the right, upon
reasonable notice, to inspect and audit 454’s books and records during normal business hours to ensure that appropriate reports are made and Third Party Royalties paid to such Third Parties as 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 5 

 
contemplated by the foregoing sentence. To the extent that CuraGen and 454 are both engaged in the exercise of rights under a license from a Third Party to
Technology included in the Core Technology, CuraGen Process Improvements or CuraGen Third Party Process Improvements, CuraGen and 454 shall mutually agree on a reasonable allocation of any Third Party Royalties due thereunder based on the relative
value of the license in the CuraGen Field and the 454 Field. 
  
 2.1.4 CuraGen Process Improvements. CuraGen shall notify 454 in writing of any patentable CuraGen Process Improvement within thirty (30) days of the filing of any patent application (including any provisional
patent application) covering such CuraGen Process Improvement, which notice shall contain a copy of such application. Immediately as of such filing date, CuraGen shall be deemed to have granted to 454 the license described in Section 2.1.1 above
with respect to such CuraGen Process Improvement. Representatives of the parties shall meet on a semi-annual basis, or more frequently at the option of either party, to disclose and exchange information and know-how regarding all CuraGen Process
Improvements, whether or not patentable. 
  
 2.1.5 CuraGen Third Party Process Improvements. CuraGen shall notify 454 in writing of any CuraGen Third Party Process Improvement which becomes Controlled by CuraGen during the term of this Agreement, which notice shall contain a
description of such CuraGen Third Party Process Improvement and any royalties that would be payable by 454 with respect to a sublicense thereof, in complete enough form to allow for proper evaluation thereof by 454. 454 shall provide CuraGen with
written notice within five (5) business days of the date of its receipt of such notice if it finds the disclosure insufficient for such evaluation. 454 shall have [********] days from the date of such notice to provide a written response to CuraGen
as to whether or not it wishes to sublicense such CuraGen Third Party Process Improvement. If the response is not received within such [********] period, as such period may be extended by written agreement of both parties, or if 454 indicates in its
response that it does not wish to obtain a sublicense to such CuraGen Third Party Process Improvement, 454 shall thereafter have no right to sublicense such CuraGen Third Party Process Improvement and CuraGen shall have no further obligation to 454
with respect thereto. If 454 indicates in its response that it wishes to obtain a license to such CuraGen Third Party Process Improvement, CuraGen shall be deemed to have granted to 454 the sublicense described in Section 2.1.1 with respect to such
CuraGen Third Party Process Improvement as of the date of such response. 
  
 2.1.6 Grant of Software License to 454. Subject to the terms and conditions of this Agreement, in furtherance of the grant of the license in Section 2.1.1 above, CuraGen hereby agrees to grant 454 a license to
certain software of CuraGen useful for the organization and analyses of expression data on substantially the terms set forth in the form of Software License Agreement attached hereto as Exhibit A (the “Software License
Agreement”). 
  
 2.1.7
Non-Competition in the CuraGen Field. Notwithstanding anything to the contrary contained herein, 454 hereby acknowledges and agrees that in partial consideration for the grant of the license in Section 2.1.1 above, during the term of this
Agreement and, following the termination of this Agreement, for a period equal to the Non-Competition Period, (i) prior to the closing of a Qualified Public Offering, 454 shall not engage independently or with any Third 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 6 

 
Party in any business, venture or activity outside the 454 Field, and (ii) after the closing of a Qualified Public Offering, 454 shall not
engage independently or with any Third Party in any business, venture or activity within the CuraGen Field. For the purposes of this Agreement, a “Qualified Public Offering” means a firm commitment underwritten public offering pursuant to
an effective registration statement under the Securities Act of 1933, as amended (or any successor statute for registration of shares in public offerings) covering the offer and sale of Common Stock of 454 for the account of 454 to the public (other
than a registration statement with respect to employee stock option or purchase plans) resulting in the aggregate receipt by 454 of at least [***********] of gross proceeds (before applicable discounts, commissions and expenses) and the listing of
the Common Stock of 454 on a nationally recognized stock market or exchange, including the Nasdaq Stock Market, the New York Stock Exchange and the American Stock Exchange. 
  
 2.1.8 Consideration for the Grant of Rights. In exchange and as consideration for CuraGen’s
grant of rights to 454 under this Section 2.1 and certain other consideration and upon the terms and subject to the conditions set forth in this Agreement, 454 has, on the Effective Date, issued and delivered to CuraGen twelve million (12,000,000)
shares of 454’s Series A Preferred Stock, $.01 par value per share (the “Shares”). 
  
 2.2. Grant of Rights to CuraGen. 
  
 2.2.1. Grant of Technology License. 
  
 (a) Scope of License. Subject to the terms and conditions of this Agreement, 454 hereby grants to CuraGen and its Affiliates a
perpetual, co-exclusive (with 454) worldwide license or sublicense (as the case may be), with the right to grant sublicenses, to 454’s interest in any Core Technology, 454 Process Improvements or 454 Third Party Process Improvements (which, in
the latter case, CuraGen elects to license pursuant to Section 2.2.1(d) of this Agreement) to exploit such Core Technology, 454 Process Improvements and 454 Third Party Process Improvements within the CuraGen Field. 
  
 (b) No Accounting; Third Party Royalties. The license
from 454 to CuraGen set forth in Section 2.2.1(a) of this Agreement shall be without a duty of accounting on the part of CuraGen to 454 and shall be royalty-free except to the extent that Third Party Royalties are due on account of CuraGen’s
exploitation of such license. Unless otherwise required by the Third Party, CuraGen hereby agrees, with respect to all Core Technology, 454 Process Improvements and 454 Third Party Process Improvements it licenses from 454 under this Agreement, to
pay all such Third Party Royalties and provide all related reports directly to the Third Party in the time periods specified by the pertinent agreements. 454 shall have the right, upon reasonable notice, to inspect and audit CuraGen’s books and
records during normal business hours to ensure that appropriate reports are made and Third Party Royalties paid to such Third Parties as contemplated by the foregoing sentence. To the extent that CuraGen and 454 are both engaged in the exercise of
rights under a license from a Third Party to Technology included in the Core Technology, 454 Process Improvements or 454 Third Party Process Improvements, CuraGen and 454 shall mutually agree on a reasonable allocation of any Third 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 7 

 
Party Royalties due thereunder based on the relative value of the license in the CuraGen Field and the 454 Field. 
  
 (c) 454 Process Improvements. During the Term of the
Agreement, 454 shall notify CuraGen in writing of any patentable 454 Process Improvement within thirty (30) days of the filing of any patent application (including any provisional patent application) covering such 454 Process Improvement, which
notice shall contain a copy of such application. Immediately as of such filing date, 454 shall be deemed to have granted to CuraGen the license described in Section 2.2.1 above with respect to such 454 Process Improvement. Representatives of the
parties either shall meet on a semi-annual basis, or more frequently at the option of either Party, to disclose and exchange information and know-how regarding all 454 Process Improvements, whether or not patentable. 
  
 (d) 454 Third Party Process Improvements. 454 shall
notify CuraGen in writing of any 454 Third Party Process Improvement which becomes Controlled by 454 during the Term of the Agreement, which notice shall contain a description of such 454 Third Party Process Improvement and any royalties that would
be payable by CuraGen with respect to a sublicense thereof, in complete enough form to allow for proper evaluation thereof by CuraGen. CuraGen shall provide 454 with written notice within five (5) business days of the date of its receipt of such
notice if it finds the disclosure insufficient for such evaluation. CuraGen shall have [*********] days from the date of such notice to provide a written response to 454 as to whether or not it wishes to sublicense such 454 Third Party Process
Improvement. If the response is not received within such [*********] period, as such period may be extended by written agreement of both parties, or if CuraGen indicates in its response that it does not wish to obtain a sublicense to such 454 Third
Party Process Improvement, CuraGen shall thereafter have no right to sublicense such 454 Third Party Process Improvement and 454 shall have no further obligation to CuraGen with respect thereto. If CuraGen indicates in its response that it wishes to
obtain a license to such 454 Third Party Process Improvement, 454 shall be deemed to have granted to CuraGen the sublicense described in Section 2.2.1 with respect to such 454 Third Party Process Improvement as of the date of such response.

  
 2.2.2. Grant of Beta Test Site
License. 454 and CuraGen hereby agree that, during the term of this Agreement, CuraGen shall have the option to serve as the exclusive beta test site for all Instruments, Reagents and Software developed by 454 for use in the CuraGen Field on
substantially the terms contained in the form of Beta and Production Product Supply Agreement attached hereto as Exhibit B (the “Beta Site Agreement”). 
  
 2.2.3. Supply of Instruments, Reagents and Software. During the term of this Agreement and on a
non-exclusive basis, 454 will sell to CuraGen for use as provided herein, and CuraGen will purchase from 454, Instruments, Reagents and Software in accordance with the terms set forth on Schedule C attached hereto. In the event there is a
conflict between this Agreement and the Beta Site Agreement with respect to the supply of Instruments, Reagents and Software, the terms of the Beta Site Agreement shall control. 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 8 

 2.3 Rights in Other Fields. 
  
 2.3.1. Rights in Other Fields. Unless prohibited by confidentiality obligations to Third Parties and
subject to any restrictions provided herein or in the Certificate of Incorporation of CuraGen, if either party becomes aware of the potential use in Other Fields of Core Technology, it shall promptly advise the other party of said use and provide a
summary of the information in its possession relating to such potential use. In the event that either party wishes to develop or commercialize any such Core Technology for any use in such Other Field, it shall first provide written notice to the
other party and shall offer the other party the right of first negotiation described in Section 2.3.2 hereof. 
  
 2.3.2. Right of First Negotiation. In the event that either party has a right of first negotiation as provided in Section 2.3.1,
the other party (the “Offering Party”) shall give written notice to the party having such right (the “Receiving Party”) specifying in reasonable detail the Other Field in which the Offering Party intends to develop and
commercialize the Core Technology and the uses within the Other Field for which the Offering Party intends to develop and commercialize such Core Technology (the “Offer”). The Receiving Party shall have [*********] days after the date of
the Offer to provide a written response to the Offering Party (the “Response”) as to whether or not it wishes to enter into negotiations with the Offering Party with respect to such rights. If the Response states that the Receiving Party
wishes to enter into negotiations with the Offering Party, the parties shall negotiate in good faith the licensing of such rights to such Core Technology for a period of [*********] days from the date of the Response. If the Response is not received
within the [*********] day response period or if the Receiving Party declines to enter into negotiations or if the parties do not agree upon and execute a written agreement within the [*********] day negotiation period, as such period may be
extended by written agreement of both parties, the Offering Party shall thereafter have the right, alone or in collaboration with a Third Party, to pursue development, commercialization or licensing of the Core Technology in such Other Field and for
the uses which were the subject of the Offer. 
  
 2.4 Corporate Opportunity. 454 hereby acknowledges that CuraGen has certain rights (a) under Section 2.3.1 hereof, to conduct business under certain conditions in Other Fields, and (b) under Section 1.1 of the Beta Agreement to
conduct business within the 454 Field, and hereby agrees that if CuraGen or any director or officer of 454 who is a director, officer or employee of CuraGen acquires knowledge of any potential transaction or matter which may be a Corporate
Opportunity or otherwise is then exploiting any Corporate Opportunity (whether such Corporate Opportunity is in the 454 Field, the CuraGen Field or Other Fields), 454 shall have no interest in, and no expectation that, such Corporate Opportunity be
offered to it, any such interest or expectation being hereby renounced so that CuraGen and such individuals (1) shall have no duty to communicate, or present such Corporate Opportunity to 454, shall have the right to hold any such Corporate
Opportunity for CuraGen’s (and its officers’, directors’, agents’, stockholders’, members’, partners’, Affiliates’ or Subsidiaries’) own account, or to recommend, assign or otherwise transfer such
Corporate Opportunity to persons other than 454 or any Subsidiary of 454, and (2) cannot be liable to 454 or its stockholders for breach of any fiduciary duty as a stockholder, officer or director of 454 or otherwise by reason of the fact that
CuraGen pursues or acquires such Corporate Opportunity for itself, directs, sells, assigns or otherwise transfers such Corporate Opportunity to another person, or does not communicate information regarding such Corporate Opportunity to 454. For
purposes of this Section 2.4, “Corporate Opportunity” shall 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 9 

 
mean an investment or business opportunity or prospective economic or competitive advantage in which 454 could, but for the provisions of this Section 2.4,
have an interest or expectancy. 
  
 2.5 Royalties on Sales of
Royalty-Bearing Services. 
  
 2.5.1
Royalties; Accounting. In consideration of the grant of the license by CuraGen hereunder, and subject to the other terms of this Agreement, commencing on the date of First Commercial Sale of any Royalty-Bearing Service and continuing for the
remainder of the Royalty Term, 454 shall pay to CuraGen a royalty of [********] of the total Net Sales of all Royalty-Bearing Services sold by 454 and/or its Affiliates and/or its sublicensees. 
  
 2.5.2 Third Party Royalty Offset. In the event that
during the Royalty Term, 454 is required (a) to enter into any agreement with any Third Party to obtain a license to an issued patent or patents in the absence of which the sale of a Royalty-Bearing Service would cause it to infringe such patent in
a given country (each, a “Third Party Agreement”) and (b) to make royalty payments under such Third Party Agreements, then, solely to the extent the royalties paid under such Third Party Agreements exceed [************], the royalties due
to CuraGen pursuant to Section 2.5.1 above for such Royalty-Bearing Service may be reduced by [************] of the amount by which such royalty payments exceed [************]; provided, that, any such reductions under this Section
2.5.2 shall in no event reduce the royalty for such Royalty-Bearing Service in any such country payable pursuant to Section 2.5.1 above to less than [************]. 
  
 2.5.3 Royalty Term. 454 shall pay royalties with respect to each Royalty-Bearing Service on a
country-by-country basis commencing on the date of First Commercial Sale of such Royalty-Bearing Service until and continuing to the later of (a) the last-to-expire of the Core Patent Rights whose claims cover the manufacture, use or sale of such
Royalty-Bearing Service in such country, or (b) [***********] years from the First Commercial Sale of such Royalty-Bearing Service in such country (the “Royalty Term”). Following such Royalty Term, 454 shall have a fully paid-up,
irrevocable, freely transferable and sublicensable license in such country under the relevant Core Patent Rights and Core Technology, to develop, have developed, make, have made, use, have used, sell, have sold, offer for sale, import and have
imported such Royalty-Bearing Service in such country. The parties hereby acknowledge and agree that (a) royalties may be payable hereunder for a Royalty-Bearing Service for which no Core Patent Rights exist or for which no license is granted by
CuraGen and (b) under such circumstances, such royalties shall be in consideration of the commercial advantage and background information gained from the license hereunder. 
  
 2.5.4 Payment Terms. 
  
 (a) Timing of Payments. 454 shall make all royalty payments owed to CuraGen in United States Dollars,
quarterly within thirty (30) days following the end of each calendar quarter for which such royalties are deemed to occur (as provided in the next sentence), using the wire transfer provisions of this Section 2.5.4. For purposes of determining when
a sale of any Royalty-Bearing Service occurs under this Agreement, the sale shall be deemed to occur on the earlier of (a) the date the Royalty-Bearing Service is shipped or provided, as the case may 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 10 

 
be or (b) the date of the invoice to the purchaser of the Royalty-Bearing Service. Each royalty payment shall be accompanied by a report for each country in
which sales of Royalty-Bearing Services occurred in the calendar quarter covered by such statement, specifying: the gross sales (if available) and Net Sales in each country’s currency; the applicable royalty rate under this Agreement; the
royalties payable in each country’s currency, including an accounting of deductions taken in the calculation of Net Sales; the applicable exchange rate to convert from each country’s currency to United States Dollars under this Section
2.5.4; and the royalties payable in United States Dollars. 
  
 (b) Foreign Currency Exchange. All royalties shall be payable in full in the United States in United States Dollars, regardless of the countries in which sales are made. For the purpose of computing Net Sales
for Royalty-Bearing Services sold in any currency other than United States Dollars, the quarterly royalty payment will be calculated as follows: 
  
 (A/B) x C = United States Dollars royalty payment on foreign sales, where 
  

	 	A =	foreign “Net Sales” (as defined above) per quarter; 

	 	B =	foreign exchange conversion rate, expressed in local currency per United States Dollar (using as the applicable foreign exchange rate the average of the rate published in the
western edition of The Wall Street Journal, or any other mutually agreed upon source, for the last business day of the calendar quarter); and 

	 	C =	the royalty rate applicable to such Net Sales under this Agreement. 

  
 (c) Tax Withholding; Restrictions on Payment. All payments hereunder shall be made free and clear of any taxes, duties, levies,
fees or charges, except for withholding taxes (to the extent applicable). 454 shall make any applicable withholding payments due on behalf of CuraGen and shall promptly provide CuraGen with written documentation of any such payment sufficient to
satisfy the requirements of the United States Internal Revenue Service relating to an application by CuraGen for a foreign tax credit for such payment. If by law, regulations or fiscal policy of a particular country, remittance of royalties in
United States Dollars is restricted or forbidden, written notice thereof shall promptly be given to CuraGen, and payment of the royalty shall be made by the deposit thereof in local currency to the credit of CuraGen in a recognized banking
institution designated by CuraGen by written notice to 454. When in any country the law or regulations prohibit both the transmittal and the deposit of royalties on sales in such country, royalty payments shall be suspended for as long a such
prohibition is in effect and as soon as such prohibition ceases to be in effect, all royalties that 454 would have been under an obligation to transmit or deposit but for the prohibition shall forthwith be deposited or transmitted, to the extent
allowable. 
  
 (d) Wire Transfers. All
payments hereunder shall be made to CuraGen by bank wire transfer in immediately available funds to the account designated by CuraGen by written notice to 454 from time to time. 
  
 2.5.5 Overdue Royalties. All royalties not paid within the time period set forth in this Article 2
shall bear interest at a rate of [************] per month from the due date until paid in full. 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 11 

 2.5.6 Records Retention; Review. 
  
 (a) Royalties. 454 and its Affiliates and/or
sublicensees shall keep for at least three (3) years from the end of the calendar year to which they pertain complete and accurate records of sales by 454, or its Affiliates and/or sublicensees, as the case may be, of each Royalty-Bearing Service,
in sufficient detail to allow the accuracy of the royalties to be confirmed. 
  
 (b) Review. At the request of CuraGen, upon at least [************] days prior written notice from CuraGen (except as otherwise provided herein), 454 shall permit an independent certified public accountant
reasonably selected by CuraGen and reasonably acceptable to 454 to inspect (during regular business hours) the relevant records required to be maintained by 454 under this Section 2.5.6. At CuraGen’s request (which shall not be made more
frequently than once per year during the term), the accountant shall be entitled to review the then-preceding three (3) years of 454’s records under this Section 2.5.6 for purposes of verifying 454’s royalty calculations. In every case the
accountant must have previously entered into a confidentiality agreement with both parties substantially similar to the provisions of Article 4 and limiting the disclosure and use of such information by such accountant to authorized representatives
of the parties and the purposes germane to this Section 2.5.6. Results of any such review shall be made available to both parties and shall be binding on both parties. CuraGen agrees to treat the results of any such accountant’s review of the
454’s records under this Section 2.5.6 as Confidential Information of 454 subject to the terms of Article 4. If any review reveals a deficiency in the calculation of royalties resulting from any underpayment by 454, 454 shall promptly pay
CuraGen the amount remaining to be paid (plus interest thereon at the rate provided in Section 2.5.5 above), and if such underpayment is by [************] or more, 454 shall pay all costs and expenses of the review. 
  
 2.6 Early Access to Royalty-Bearing Services. In partial consideration
of the rights granted to it hereunder, 454 hereby agrees for a period of not less than [*******] months prior to the provision by it of any Royalty-Bearing Service and/or the shipment by it to any Third Party of an Instrument that provides a
Royalty-Bearing Service, it will first offer such Royalty-Bearing Service exclusively to CuraGen, under either the Beta Site Agreement or under a separate agreement, as the case may be, on the terms set forth on Schedule C attached hereto and
such additional terms as may be mutually acceptable to the parties. 
  
 2.7 Approval of Certain Contracts. Notwithstanding anything to the contrary contained in this Agreement, 454 hereby agrees that during the period commencing on the Restated Effective Date and continuing through
[***********************], without the prior written approval of CuraGen, it shall not enter into any agreement (a) [***************************************** 
 ********************************************************************] or (b) [***************************** 
 ****************************************************************] or (c) [******************************* 
 ******************************************]. 454 hereby further agrees that CuraGen may withhold any approval under subsection (a) above if CuraGen determines, (i) [************************************************************** 

********************************************************] 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 12 

 
or (ii) [************************************************************************ **************************]. 
  
 2.8 Sales to Human Health Care Companies. The Parties hereby agree
that during the period commencing on the Restated Effective Date and continuing through the [****************************] all promotional activities by 454 with respect to human health care companies shall be performed in accordance with
Schedule D attached hereto. 
  
 2.9 Sequencing Services
for CuraGen. 454 hereby agrees that it shall perform any Sequencing Services that CuraGen may request in writing from time to time during the term of this Agreement either for itself or as part of a collaboration at its fully-burdened cost. Any
collaboration work that is solely Sequencing Services (to which CuraGen consents) will be priced at market and 454 will pay CuraGen the Section 2.5 royalty. 
  
 ARTICLE 3. LIMITATION OF LIABILITY 
  
 3.1. CuraGen Limitation of Liability and Right to Indemnification. CuraGen and its Affiliates, and their respective directors, officers, employees
and agents, shall not be liable for any loss, damage, injuries or other casualty of any kind, or by whomsoever caused, to the person or property of anyone, including 454, arising out of or resulting from (i) the lack of freedom of 454 to use the
Core Technology, any CuraGen Process Improvement or any CuraGen Third Party Process Improvement without infringing the intellectual property rights of any Third Party (except to the extent represented by CuraGen in Section 5.1(d) of this Agreement)
or (ii) the use of the Core Technology, any CuraGen Process Improvement or any CuraGen Third Party Process Improvement in any product made, used or sold or service (including any Instrument or Royalty-Bearing Service) performed by 454 or a licensee
of 454 (except CuraGen) (a “CuraGen Loss”). 454, for itself, its successors and assigns, shall indemnify and hold CuraGen and its Affiliates, and their respective directors, officers, employees and agents, harmless from and against
any and all claims, demands, liabilities, suits or actions, actual or threatened (including all reasonable expenses and attorney’s fees incurred or imposed on CuraGen in connection therewith) for any CuraGen Loss. 
  
 3.2. 454 Limitation of Liability and Right to Indemnification. 454 and
its Affiliates, and their respective directors, officers, employees and agents, shall not be liable for any loss, damage, injuries or other casualty of any kind, or by whomsoever caused, to the person or property of anyone, including CuraGen arising
out of or resulting from (i) the lack of freedom of CuraGen to use the Core Technology, any 454 Process Improvement or any 454 Third Party Process Improvement without infringing the intellectual property rights of any Third Party or (ii) the use of
the Core Technology, any 454 Process Improvement or any 454 Third Party Process Improvement in any product made, used or sold or service performed by CuraGen or a licensee of CuraGen (except 454) (a “454 Loss”). CuraGen, for itself,
its successors and assigns, shall indemnify and hold 454 and its Affiliates, and their respective directors, officers, employees and agents, harmless from and against all claims, demands, liabilities, suits or actions, 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 13 

 
actual or threatened (including all reasonable expenses and attorney’s fees incurred or imposed on 454 in connection therewith) for any 454 Loss.

  
 3.3. Indemnification Procedures. 
  
 A party seeking indemnification under this Article 3 (the “indemnified
party”) shall give prompt notice of the claim to the other party (the “indemnifying party”). If the indemnifying party is not contesting the indemnity obligation, the indemnified party shall permit the indemnifying party to control
any litigation or threatened litigation relating to such claim and the settlement or other disposition of any such claim, provided that the indemnifying party shall act reasonably and in good faith with respect to all matters relating to the defense
and settlement or other disposition of any such claim as the settlement or other disposition relates to the persons being indemnified under this Article 3 and the indemnifying party shall not settle or otherwise resolve any such claim without prior
notice to the indemnified party. If the settlement or other disposition of any such claim involves anything other than the payment of money by the indemnifying party, the consent of the indemnified party shall be required, which consent shall not be
unreasonably withheld or delayed. The indemnified party shall cooperate with the indemnifying party in its defense of any claim for which indemnification is sought under this Article 3. 
  
 ARTICLE 4. TREATMENT OF CONFIDENTIAL INFORMATION 
  
 4.1. Confidential Information. CuraGen and 454 each recognizes that the other party’s Confidential Information
constitutes highly valuable and proprietary confidential information. Subject to the right of each party to exploit the licenses granted to it in Article 2 of this Agreement in keeping with the terms and conditions of Article 2 of this Agreement,
CuraGen and 454 each agrees that it will keep confidential and will cause its employees, consultants, Affiliates, licensees and sublicensees to keep confidential, all Confidential Information of the other party that is disclosed to it, or to any of
its employees, consultants, Affiliates, licensees and sublicensees, pursuant to or in connection with this Agreement. Neither CuraGen nor 454 nor any of their respective employees, consultants, Affiliates, licensees and sublicensees shall use
Confidential Information of the other party for any purpose whatsoever except as expressly permitted in this Agreement. In the event that either party desires to make a presentation or disclosure to any potential licensee or sublicensee which
includes Confidential Information relating to the Core Technology, such party shall do so solely under the terms of an agreement that imposes non-disclosure and non-use restrictions on the potential licensee or sublicensee. 
  
 4.2. Representation. CuraGen and 454 each represent that all of its
employees and the employees of its Affiliates, and any consultants to such party or its Affiliates, who shall have access to Confidential Information of the other party are bound by written obligations to maintain such information in confidence and
not to use such information except as expressly permitted herein. Each party hereby agrees to enforce all such confidentiality obligations to which its employees and consultants and those of its Affiliates are obligated. 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 14 

 4.3. Proprietary Materials. For purposes of this Section, “Proprietary Materials”
means confidential or proprietary tangible biological, chemical, or physical materials (“Materials”) that are developed, discovered, or acquired by a party and which are furnished by one party (the “Supplier”) to
the other party (the “Recipient”) in connection with the performance of this Agreement. The Recipient shall not use Proprietary Materials for any purpose other than exercising any rights granted to it or reserved by it hereunder.
The Recipient shall use the Proprietary Materials only in compliance with all applicable federal, state, and local laws and regulations. The Recipient shall not transfer any Proprietary Materials to any third party without the prior written consent
of the Supplier, except as expressly permitted hereby. Upon the expiration or termination of this Agreement, the Recipient shall at the instruction of Supplier either destroy or return any unused Proprietary Materials, which is not the subject of
the grant of a continuing license hereunder. 
  
 4.4.
Publicity. Neither party may publicly disclose the terms of this Agreement without the prior written consent of the other party; provided, however, that either party may make such a disclosure to the extent required by law or by
the requirements of any nationally recognized securities exchange, quotation system or over-the-counter market on which such party has its securities listed or traded. The parties, upon the execution of this Agreement, will agree to a news release
for publication in general circulation and industry periodicals; provided, however, that such news release shall be issued only at such time as both parties mutually agree. Once any written statement is approved for disclosure by both parties,
either party may make subsequent public disclosure of the contents of such statement without the further approval of the other party.  
  
 ARTICLE 5. REPRESENTATIONS AND WARRANTIES 
  
 5.1. Representations, Warranties and Covenants of CuraGen. CuraGen represents, warrants and covenants to 454 as follows: 
  
 (a) CuraGen is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware with corporate powers adequate for executing, delivering and performing its obligations under this Agreement. 
  
 (b) The execution, delivery and performance of this Agreement have been duly authorized by all necessary
corporate action on the part of CuraGen. 
  
 (c)
The execution, delivery and performance of this Agreement do not and will not conflict with or contravene any provision of the charter documents or by-laws of CuraGen or any agreement, document, instrument, indenture or other obligation of CuraGen.

  
 (d) To its knowledge, CuraGen owns and has
the right to license the Core Technology and the consummation of the transactions contemplated by this Agreement will not alter or impair such right. To its knowledge, no material claims have been asserted against CuraGen, and no claims are pending
against CuraGen in writing, regarding CuraGen’s 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 15 

 
ownership or use of the Core Technology. CuraGen makes no representations or warranties of non-infringement of the proprietary rights of other parties.

  
 5.2. Representations, Warranties and Covenants of 454.
454 represents, warrants and covenants to CuraGen as follows: 
  
 (a) 454 is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware with corporate powers adequate for executing and delivering, and performing its obligations under
this Agreement. 
  
 (b) The execution, delivery
and performance of this Agreement and the Shares have been duly authorized by all necessary corporate action on the part of 454. 
  
 (c) The execution, delivery and performance of this Agreement and the Shares do not and will not conflict with or contravene any provision
of the charter documents or bylaws of 454 or any agreement, document, instrument, indenture or other obligation of 454. 
  
 ARTICLE 6. PATENT PROSECUTION AND INFRINGEMENT 
  
 6.1. Rights in the Core Technology. 454 shall be responsible, at 454’s sole expense, for the preparation, filing and prosecution and
maintenance of such patent applications and patents included in the Core Patent Rights as 454 shall determine in its sole discretion; provided, however, that upon the request of CuraGen, 454 shall use patent counsel selected by CuraGen, the caliber
of whom shall be reasonably acceptable to 454; and, provided further, that CuraGen shall reimburse 454 for the cost of preparation, filing, prosecution and maintenance of all such patent applications and patents that are directed primarily to the
CuraGen Field. 454 shall keep CuraGen’s Patent Coordinator (as defined below) informed as to the status of the patent applications and the patents included in the Core Technology and shall consult with CuraGen’s Patent Coordinator with
respect to any substantive decisions and communications in such prosecutions and shall give due consideration to the advice and comments of the CuraGen Patent Coordinator; provided, however, that any such decision and the substance of
any such communication shall be finally determined by 454 in its sole discretion. Such patent counsel shall provide copies to CuraGen of all filings and correspondence with any patent offices, administrative boards or courts which 454 sends or
receives in connection with the filing, prosecution or maintenance of the Core Patent Rights, and shall provide CuraGen with advance drafts of all substantive communications to be made by 454 with any patent offices, administrative boards or courts
in connection with the filing, prosecution or maintenance of the Core Patent Rights. 454 shall provide advance written notice to CuraGen if, for any reason, it elects not to perform or continue the preparation, filing, prosecution or maintenance of
any of the patent applications or patents included in the Core Patent Rights, in which case, CuraGen shall have the right to do so at its sole expense; provided, however, that if CuraGen shall so elect to perform or continue the preparation, filing,
prosecution or maintenance of any of the patent applications or patents included in the Core Patent Rights, 454 shall, at its election, either (i) give up its license with respect to such patent applications or patents or (ii) reimburse CuraGen for
all reasonable expenses incurred to perform or continue the preparation, filing, prosecution or 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 16 

 
maintenance of such patent applications or patents. If, pursuant to the preceding sentences, CuraGen assumes responsibility for the preparation, filing,
prosecution or maintenance of any patent applications or patents included in the Core Patent Rights, 454 shall fully cooperate and assist CuraGen in furtherance thereof. 
  
 6.2. Patent Coordinators. CuraGen and 454 shall each appoint a “Patent Coordinator” who shall be a person
designated from time to time to serve as such Party’s primary liaison with the other Party on matters relating to patent filing, prosecution, maintenance and enforcement specified in this Article 6. Each Party may replace its Patent Coordinator
at any time by notice in writing to the other Party. The initial Patent Coordinators shall be: 
  
 For CuraGen (the “CuraGen Patent Coordinator”): [****************] 
  
 For 454 (the “454 Patent Coordinator”): [**************] 
  
 6.3. Notification of Infringement or Breach. Each party shall notify the other of any infringement of any patent
included in the Core Technology, or of any breach of any agreement pertaining to Confidential Information by any person and shall provide the other with the available evidence, if any, of such infringement or breach, in each case to the extent known
to such party. 
  
 6.4. Enforcement of Rights in the Core
Technology. If CuraGen or 454 has actual notice of infringement of any Core Technology, the respective officers of CuraGen and 454 shall confer to determine in good faith an appropriate course of action to enforce the parties’ rights in
such Core Technology or otherwise abate the infringement. If 454 determines that enforcement of the parties’ rights in the Core Technology is appropriate, 454 shall have the right, but not the obligation, at its own expense, to take appropriate
action to enforce such right; provided, however, that if 454 elects to so act, CuraGen shall have the right to participate in such enforcement by agreeing to bear a percentage of the costs of such enforcement in such amount as the
parties shall determine not to exceed [************]. All amounts recovered in any action to enforce the parties’ rights in the Core Technology undertaken by 454 and CuraGen, whether by judgment or settlement, shall be retained by 454 and
CuraGen pro rata according to the respective percentages of expenses borne by them in enforcing their rights to the Core Technology rights. If, within a reasonable period of time after notice of such infringement or breach, 454 has not commenced
action to enforce such rights or thereafter ceases to pursue diligently such action, CuraGen shall have the right, but not the obligation at its expense, to take appropriate action to enforce such rights as its sole remedy hereunder. All amounts
recovered in any action to enforce Core Technology rights undertaken by CuraGen at its expense, whether by judgment or settlement, shall be retained by CuraGen. CuraGen and 454 shall fully cooperate with each other in the planning and execution of
any action to enforce their rights in the Core Technology. Neither CuraGen nor 454 shall enter into any settlement that includes a license to use the Core Technology in a field reserved for or exclusively licensed to the other party hereunder, an
agreement not to enforce the Core Technology or any statement prejudicial to the validity or enforceability of the Core Technology without the consent of the other party, which consent shall not be unreasonably withheld or delayed. 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 17 

 6.5. Rights in Improvements. Each party shall be responsible, at its sole expense, for the
preparation, filing and prosecution and maintenance of such patent applications and patents pertaining to improvements made by such party to the Core Patent Rights as it shall determine in its sole discretion. 
  
 6.6. Limitation on Warranties. Nothing in this Agreement shall be
construed as a representation made or warranty given by either party hereto that any license granted hereunder, or that the use of any Technology licensed hereunder, will not infringe the patent or proprietary rights of any other person. IN
ADDITION, 454 ACKNOWLEDGES THAT THE CORE TECHNOLOGY, ANY CURAGEN PROCESS IMPROVEMENT AND/OR ANY CURAGEN THIRD PARTY PROCESS IMPROVEMENT IS LICENSED TO 454 AS IS AND 454 EXPRESSLY HEREBY WAIVES ANY WARRANTY, EXPRESS OR IMPLIED, WITH RESPECT TO SUCH
TECHNOLOGY OF 454, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. CURAGEN ACKNOWLEDGES THAT THE CORE TECHNOLOGY, ANY 454 PROCESS IMPROVEMENT AND/OR ANY 454 THIRD PARTY PROCESS IMPROVEMENT IS
LICENSED TO CURAGEN AS IS AND CURAGEN EXPRESSLY HEREBY WAIVES ANY WARRANTY, EXPRESS OR IMPLIED, WITH RESPECT TO SUCH TECHNOLOGY OF 454, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 

 
 6.7. Limitation on Damages. NEITHER PARTY TO THIS AGREEMENT SHALL
BE ENTITLED TO RECOVER FROM THE OTHER ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES UNDER ANY CIRCUMSTANCES. 
  
 ARTICLE 7. TERM 
  
 7.1. Term. Subject only to Section 7.2 of this Agreement, this Agreement shall be effective as of the date hereof and shall continue in full force
and effect in perpetuity, it being understood that, in the event of a termination by a Third Party of a party’s license to any Technology sublicensed to the other party hereunder, the other party’s sublicense to such Technology shall
terminate upon the termination of such license by the Third Party. 
  
 7.2. Termination. 
  
 7.2.1.
Right to Terminate for Breach. CuraGen shall have the right to terminate this Agreement (including without limitation the license granted under Section 2.1 of this Agreement) in the event 454 breaches this Agreement by giving thirty (30) days
written notice thereof to 454. 
  
 7.2.2.
Right to Terminate for Bankruptcy. In the event that either party files for protection under bankruptcy laws, makes an assignment for the benefit of creditors, appoints or suffers appointment of a receiver or trustee over its property,
files a petition under any bankruptcy or insolvency act or has any such petition filed against it which is not discharged 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 18 

 
within sixty (60) days of the filing thereof, then the other party may terminate this Agreement effective immediately upon written notice to such party.

  
 7.2.3. Surviving Provisions.
Termination of this Agreement for any reason shall be without prejudice to rights which expressly survive termination in accordance with the terms of this Agreement, including without limitation, rights that survive under Articles 3 and 4 and
Sections 7.2.3, 8.1,8.6, 8.9 and 8.10, all of which shall survive such termination. 
  
 ARTICLE 8. MISCELLANEOUS 
  
 8.1. Notices. All notices, requests and other communications to CuraGen or 454 hereunder shall be in writing, shall refer specifically to this Agreement, and shall be (a) personally delivered, (b) sent by facsimile transmission, (c)
sent by certified mail, return receipt requested, postage prepaid, or (d) sent by recognized courier service providing evidence of delivery, in each case to the respective address specified below (or to such address as may be specified in writing in
accordance herewith to the other party hereto): 
  

					
	If to CuraGen:	 	CuraGen Corporation	 	 
	 	 	555 Long Wharf Drive	 	 
	 	 	New Haven, CT 06511	 	 
	 	 	Attention: President	 	 
	 	 	 	 	 
	If to 454:	 	454 Life Sciences	 	 
	 	 	20 Commercial Street	 	 
	 	 	Branford, CT06405	 	 
	 	 	Attention: President	 	 
	 	 	 	 	 
	In each case, with a copy to:	 	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.	 	 
	 	 	One Financial Center	 	 
	 	 	Boston, MA 02111	 	 
	 	 	Tel.: (617) 542-6000	 	 
	 	 	Fax: (617) 542-2241	 	 
	 	 	Attention: Jeffrey M. Wiesen, Esq.	 	 

  
 Any notice or
communication given in conformity with this Section 8.1 shall be deemed to be effective when received by the addressee, if delivered by hand or by courier, when confirmed by the addressee if delivered by facsimile and five (5) days after mailing, if
mailed. 
  
 8.2. Entire Agreement. This Agreement
constitutes, on and as of the date hereof, the entire agreement of CuraGen and 454 with respect to the subject matter hereof, and all prior or contemporaneous understandings or agreements, whether written or oral, between CuraGen and 454 with
respect to such subject matter are hereby superseded in their entirety. 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 19 

 8.3. No Implied Waivers: Rights Cumulative. No failure on the part of CuraGen or 454 to exercise
and no delay in exercising any fight, power, remedy or privilege under this Agreement, or provided by statute or at law or in equity or otherwise, shall impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be
construed as a waiver of any breach of this Agreement or as an acquiescence therein, nor shall any single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the exercise of any other
right, power, remedy or privilege. 
  
 8.4. Amendments.
This Agreement may be amended, modified, superseded or canceled, and any of the terms may be waived, only by a written instrument executed by each party or, in the case of waiver, by the party or parties waiving compliance. The delay or failure of
any party at any time or times to require performance of any provisions shall in no manner affect the rights at a later time to enforce the same. No waiver by any party of any condition or of the breach of any term contained in this Agreement,
whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. 
  
 8.5. Successors and Assigns. The terms and provisions of this
Agreement shall inure to the benefit of, and be binding upon, CuraGen and 454, and their respective successors and assigns. 
  
 8.6. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Connecticut, without regard to
the application of principles of conflicts of law. 
  
 8.7.
Force Majeure. Neither CuraGen nor 454 shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural
disasters or any causes beyond the reasonable control of CuraGen or 454. In event of such force majeure, the party affected thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder.

  
 8.8. Further Assurances. Each of CuraGen and 454 agrees
to duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including, without limitation, the execution of such additional assignments, agreements,
documents and instruments, that may be necessary or as the other party hereto may at any time and from time to time reasonably request in connection with this Agreement or to carry out more effectually the provisions and purposes of, or to better
assure and confirm unto such other party its rights and remedies under, this Agreement. 
  
 8.9. Severability. If any provision hereof should be held invalid, illegal or unenforceable in any respect in any jurisdiction, then, to the fullest extent permitted by law, (a) all other provisions hereof
shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the parties hereto as nearly as may be possible and (b) such invalidity, illegality or unenforceability shall not
affect the validity, legality or enforceability of such provision in any other jurisdiction. To the extent permitted by 

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 20 

 
applicable law, CuraGen and 454 hereby waive any provision of law that would render any provision hereof prohibited or unenforceable in any respect.

  
 8.10. Headings. Headings used herein are for
convenience only and shall, not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. 
  
 8.11. Interpretation. Each of CuraGen and 454 hereby acknowledges and agrees that: (i) each party and its counsel reviewed and negotiated the terms
and provisions of this Agreement and have contributed to its revision; (ii) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement; and (iii)
the terms and provisions of this Agreement shall be construed fairly as to all parties hereto and not in a favor of or against any party, regardless of which party was generally responsible for the preparation of this Agreement. 
  
 8.12. Execution in Counterparts. This Agreement may be executed in any
number of counterparts, each of which counterparts, when so executed and delivered, shall be deemed to be an original, and all of which counterparts, taken together, shall constitute one and the same instrument. 
  
 8.13. Termination of Original Agreement. The parties acknowledge and
agree that (a) the Original Agreement is hereby terminated as of the Restated Effective Date and (b) except as provided in this Agreement, all rights, obligations and licenses of 454 and/or CuraGen under the Original Agreement shall terminate and
shall be of no further force and effect on and after such Restated Effective Date. 
  
 [Remainder of page intentionally left blank] 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 21 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed in their respective
corporate names by their respective authorized representatives as of the date first above written. 
  

			
	 CURAGEN CORPORATION

		
	By:	 	 /s/    CHRISTOPHER K. MCLEOD

	 	 	

	 Name: Christopher K. McLeod

	 Title: Executive Vice President

  

			
	 454 CORPORATION

		
	By:	 	 /s/    RICHARD BEGLEY

	 	 	

	 Name: Richard Begley

	 Title: Chief Executive Officer and President

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 22 

 Schedule A 
  

Core Patent Rights 
  
 Pending Patent Applications 
  

					
	 Filing Date

	 	 Serial Number

	 	 Title

	 [*********************]
	 	[*********************]	 	[*********************]
	 [*********************]
	 	[*********************]	 	[*********************]

  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 23 

 Schedule B 
  

Third Party Royalties 
  
 None 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 24 

 Schedule C 
  

Terms of Supply of Instruments, Reagents and Software 
  
 The transfer price for all Instruments, Reagents and Software supplied by 454 to CuraGen under Section 2.2.3 of this
Agreement shall be equal to the lower of (a) [**********************************************************************] and (b) [********************************************************************************************************** 
 * ********************] 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 25 

 Schedule D 
  

Sales to Human Health Care Companies 
  
 [******************************************************************************************************* 
 *******************************************************************************************************] 
  
 [******************************************************************************************************* 
 *******************************************************************************************************] 
  
 [******************************************************************************************************* 
 *******************************************************************************************************] 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 26 

 EXHIBIT A 
  
 Form of Software License Agreement 
  
 See Tab 5 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 27 

 EXHIBIT B 
  
 Form of Beta Site Agreement 
  
 See Tab 6 
  

 Certain confidential information contained in this Exhibit, marked by brackets and asterisks, were omitted and have
been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. 
  
 28

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00062-of-00352.parquet"}]]